Podcasts about eli lily

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Hurricane aid for people with diabetes, Medtronic safety warning, stem cell updates for type 1, new study about teens and young adults with type 1, and Ryan Reed returns to racing. Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Hurricane Insulin efforts XX Medtronic has notified customers that battery issues with its Minimed 600 and 700 series insulin pumps could cause the devices to stop delivering insulin significantly sooner than expected. A “low battery pump” alert, intended to signal up to 10 hours of remaining battery life, may be displayed on the device even if much less time is left. Medtronic told customers they could contact the company to determine the need for a replacement pump. Medtronic said it received 170 reports of hyperglycemia and 11 reports of diabetic ketoacidosis in the U.S., from January 2023 to September 2024, potentially related to the issue. Pump models including the Minimed 630G, 670G, 770G and 780G systems are affected by the notice. https://www.medtechdive.com/news/Medtronic-Minimed-insulin-pumps-recall-battery-life/729019/ XX A woman has undergone a stem-cell therapy made from her own cells, to treat her type 1 diabetes. Researchers in China discovered the woman did not need to use insulin 75 days after the procedure, and that the stem-cell derived islet cells she was injected with had been engrafted inside her abdomen. the case is the first of its kind, and two more people have been enrolled in the clinical trial in China since, researchers involved in the study told Medical News Today. Other stem-cell based therapies for type 1 and type 2 diabetes are also currently in development and in trials. For this case study, researchers based in Tianjin First Central Hospital, Nankai University, Tianjin, China took fat cells from a 25 year-old woman with type 1 diabetes, and chemically induced them to behave as pluripotent stem cells, a type of cell that can develop into other types of cell. They then used these to create islet cells, which typically exist in the pancreas and create insulin, a hormone that regulates levels of glucose (sugar) in the bloodstream. The patient in this case study had previously had two liver transplants and a failed pancreas transplant due to complications that had arisen due to her diabetes. The induced islet cells made from the patient's own cells were then injected between the skin and abdominal muscles. Researchers discovered that these successfully engrafted in the patient, including growing their own vasculature. Before the procedure she produced enough insulin to reach her target glycemic range 43.18% of the time, and 4 months later this increased to 96.2% of the time. She was also shown to have lower glycated hemoglobin, which indicated long-term systemic glucose levels at a non-diabetic level.   https://www.medicalnewstoday.com/articles/stem-cell-therapy-reverses-type-1-diabetes-in-groundbreaking-case-study XX The state of Texas is accusing major pharmacy benefit managers and drug companies of colluding to raise the cost of insulin.   Texas alleged drug manufacturers Eli Lilly, Novo Nordisk and Sanofi raise the price of insulin and then pay an undisclosed amount back to PBMs Optum Rx, Express Scripts and CVS Caremark through a quid pro quo agreement. PBMs then give preferred status on its standard formularies to drugs with the highest list prices, the state said. Insulin costs $2 to produce and could be purchased for $20 in the 1990s but now costs up to $700, the Office of the Attorney General of Texas wrote in a news release. The filing goes so far as to describe a LinkedIn group these executives would use to discuss insulin pricing tactics. The Federal Trade Commission (FTC) recently sued Optum Rx, Express Scripts and Caremark for rising insulin prices and anticompetitive practices. The PBMs reject the FTC's findings. Drug manufacturers were not included in the lawsuit. Texas' lawsuit also noted the consolidation in the PBM market, arguing it gives PBMs a “disproportionate amount of market power.” Nearly 40 PBM entities have now been consumed by UnitedHealth Group, Cigna and CVS Caremark. https://www.fiercehealthcare.com/payers/texas-sues-pbms-manufacturers-over-insulin-conspiracy XX Canadian teens and young adults living with diabetes face double the risk of hospitalizations and emergency room visits compared with younger children with the condition, say doctors suggesting changes to how care is organized for affected families. In the October issue of the journal The Lancet Diabetes and Endocrinology, Dr. Meranda Nakhla, a pediatric endocrinologist at the Montreal Children's Hospital, and her team used Quebec health administrative data to estimate the risk of gaps in regular diabetes care for complications in children under 10, and adults up to age 23.   "With adolescents and young adults, [the complication]  tends to be more related to an insulin omission and maybe just feeling burnt out from having diabetes and just not wanting to deal with it," Nakhla said. "They may stop taking insulin and a day later end up in the emergency room with diabetic ketoacidosis." Part of the challenge, Nakhla said, is for parents to take a step back from managing all aspects of their child's diabetes to a more supportive role that allows the child to have more autonomy. What's new about the Quebec findings is they highlight how gaps in diabetes care visits start at a younger age than previously looked at, said Dr. Rayzel Shulman, a pediatric endocrinologist at Toronto's Hospital for Sick Children. Since the brains of adolescents and young adults aren't fully developed, planning ahead, thinking about the consequences of their actions and controlling impulses differs from their parents. As part of an ongoing study, Shulman's team uses text messages to send adolescents and young adults appointment reminders as well as monthly diabetes messages. They recently added an artificial intelligence chat bot programmed with answers from trusted sources. https://www.cbc.ca/news/health/diabetes-pediatric-1.7345526 XX A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and Zepbound has filed a lawsuit against the Food and Drug Administration (FDA) for declaring an end to the shortage, effectively halting the sale of “copycat” versions of these drugs.   On Oct. 2, the FDA announced that the nearly two-year-long shortage of tirzepatide, the active ingredient in Mounjaro and Zepbound, had ended. This was after the agency said it had confirmed the manufacturer, Eli Lily, had a manufacturing capacity that “can meet the present and projected national demand.”     With the shortage over, the ability of compounding pharmacies to sell unbranded, replicated versions of these drugs came to a near halt. There are two types of compounding pharmacies: 503A and 503B. The Outsourcing Facilities Association (OFA) represents 503B compounding pharmacies, which can create prescription-specific compounded drugs as well as bulk orders.   The OFA and the compounding pharmacy North American Custom Laboratories filed their lawsuit against the FDA on Monday, alleging the agency was “abruptly depriving patients of much needed treatment and artificially raising drug prices.”   “Ignoring evidence that the shortage persists, FDA removed Tirzepatide from the shortage list without notice, without soliciting input from affected parties and the public, and without meaningful rationale,” said their complaint.   The evidence that the plaintiffs cited for the shortage persisting was that the FDA noted in its announcement that “patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies.”   Eli Lilly made a similar statement after the shortage was declared over, saying, “Patients' experiences looking for a particular dose of medicine in their local pharmacies may vary. The supply chain is complex, especially for refrigerated medicines, and there may be many reasons why a particular pharmacy does not have a particular dose of the medicine in stock. ” https://thehill.com/policy/healthcare/4922234-trade-group-sues-fda-over-ending-mounjaro-zepbound-shortage/ XX New project in Europe to provide data to enable more people with diabetes who use insulin to work as commercial pilots and air traffic controllers. The European Union Aviation Safety Agency project focuses mainly on pilots and air traffic controllers, but the data being collected will apply to cabin crew and passengers with diabetes as well   currently only three countries in Europe — the United Kingdom, Ireland, and Austria — allow them to obtain a license that enables them to fly commercially, under a strict protocol that was first launched by the UK Civil Aviation Authority in 2012. The Irish Aviation Authority joined in 2015, and Austro Control followed in 2016.     https://www.medscape.com/viewarticle/eu-program-aims-ensure-safety-pilots-who-use-insulin-2024a1000ia6 XX Edgepark commercial XX The two-time Xfinity Series winner was competing at Talladega in McAnally-Hilgeman Racing's No. 91 truck for his first start of the season. The last time Reed drove in a NASCAR event came last fall at Las Vegas Motor Speedway in the Xfinity Series, and his most recent Truck start came in the spring of 2021 at Darlington Raceway.   “I couldn't stop making mistakes early on,” Reed said. “The truck was so fast. I think more than anything I'm really proud of myself for being able to get out there and make aggressive pushes and be able to kind of rise to the occasion.”   See also Grant Enfinger Wins Talladega, Advances to Championship 4 Despite the speed, Reed's truck burst into flames shortly after crossing the finish line. Reed said he stared at the door of teammate Christian Eckes while he crossed the line in the middle of a multi-truck pileup.     “Gosh, we could go anywhere we wanted today,” Reed told Frontstretch. “I made a lot of mistakes, but we put ourselves in position at the end. I hate that Bill [McAnally] has torn up race trucks.”   Friday marked Reed's sixth start in the past six years in Truck and Xfinity equipment, something Reed said might have added some doubt.   “When you're sitting on the couch every weekend, you think you can do it,” he reflected. “I remember I used to race every single weekend, I know how to get around these plate tracks, but you don't know, right?   “It's really gratifying to come off the couch and remind myself, like ‘hey I can still do this,' at least at superspeedways. I think I can do it at other tracks too.”     The day ended in a combination of a career-best Truck Series finish and a ball of fire for Ryan Reed in his return to NASCAR Craftsman Truck Series competition on Friday (Oct. 4).   https://frontstretch.com/2024/10/04/ryan-reed-scores-career-best-finish-in-truck-series-return/ XX Join us again soon!

Sulochana Gawande is the author of the book “Revealing the Secrets of Cancer: An Informative Guide to Treatment, Prevention and Recovery”. Previously, she studied and led cancer-specific research for 4 decades in India and the US at Novartis, Eli Lily, Cancer Research Institute (Mumbai), Tata Memorial Center. --- Support this podcast: https://podcasters.spotify.com/pod/show/theindustryshow/support

Lost Scissors shuts down airport… German traveler to the United States… Disney reverses course… chewingthefat@theblaze.com Top searched Game Shows… JLO finally files… Call Her Daddy inks a new deal... Who Died Today: Maria Branyas Morera 117… Centenarians / SuperCentarians… Elizabeth Francis oldest in U.S. 115… Mike Lynch still missing… Starbucks CEO new deal… Subway has new deal… Eli Lily tirzepatide study… Thought of the Day…   Learn more about your ad choices. Visit megaphone.fm/adchoices

Wall Street rallied overnight, ending near best levels after jobless claims fell more than expected, easing concerns that the labour market was weakening too quickly. The S&P 500 rose 2.30%, its biggest daily gain since November 2023. All major sectors finished the green, led by tech stocks, although pharmaceutical stock Eli Lily was the biggest winner, up 9.47% after raising its annual profit forecast. The NASDAQ Composite gained 2.87%, while the NASDAQ 100 rose 3.06%, buoyed by gains in the magnificent seven. The Dow traded higher all session, finishing up 683 points (+1.76%), up 745 points at best. Small firms Russell 2000 also gained 2.42%, and Wall Street's fear gauge, the VIX fell 14.58%. Initial jobless claims fell by 17k to 230k, below expectations of 240k, results were received positively by the market but remain significantly above this year's claim average, signalling a softening jobs market. Treasury yields ticked higher, the 10Y yield up 3.7bps and cryptocurrencies saw a surge, Bitcoin jumped 8.51%.ASX to rally on the opening bell. SPI Futures up 81 points (+1.06%)COMMODITIESOil settles up for third straight day on US job data and Mideast tensions.Gold rises more than 1% on safe-haven demand, Fed rate-cut optimism.Copper steadies on China consumption, interest rate hopes.US refiners trim Q3 output amid weaker margins, plant overhauls.Why not sign up for a free trial? Get access to expert market insights and manage your investments with confidence. Ready to invest in yourself? Join the Marcus Today community.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Immune checkpoint inhibitors and the heart HDL, HDL therapies and cardiovascular risk Diagnostics Made Easy: the FBI syndrome Host: Susanna Price Guests: Carlos Aguiar, Alexander Lyon, Francois Mach Want to watch that episode? Go to: https://esc365.escardio.org/event/1147   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Francois Mach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic. Alexander Lyon has declared to receive speaker, advisory board or consultancy fees and/or research grants from Janssens-Cilag Ltd, Astellas Pharma, Pfizer, Novartis, Servier, Astra Zeneca, Bristol Myers Squibb, GSK, Amgen, Takeda, Roche, Clinigen Group, Eli Lily, Eisai Ltd, Ferring Pharmaceuticals, Boehringer Ingelheim, Akcea Therapeutics, Myocardial Solutions, iOWNA Health and Heartfelt Technologies Ltd. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

This week the boys discuss Eli Lily's new ob*sity ad campaign, Pinterest's roll-out of body-type searches, and NPR's feature on body-positive hikers. Then we talk about the difference between meeting online vs IRL.

Tercera hora de Visión Global que dedicamos a nuestro consultorio de Wall Street con Rafael Ojeda, de Fortage Funds. Con él hablamos de compañías como Edwards Lifesciences, Walmart, 3M, Amazon, Carvana, Heico, CDW Common, Accenture, Qualcom, Coupang, Arch Capital, Broadcom, Micron, IBM, Intuitive Surgical, Meta, Eli Lily, Colgate-Palmolive y Waters Corp. Después, último repaso a la actualidad. Terminamos con el último análisis de la jornada en el que nos acompaña Joaquín Robles, analista de XTB. Con él analizamos la situación en los mercados en una jornada marcada por nuevas subidas en los índices de Wall Street a pesar de un dato de inflación en EEUU peor de lo esperado. También hablamos de las nuevas subidas en la tecnología estadounidense al calor del acuerdo comercial anunciado por Oracle y Nvidia. También preguntados al experto por las cuentas que va a presentar Inditex mañana y que cerrarán la temporada de resultados en España.

President Biden addresses a divided Congress and nation, laying out the fight for democracy abroad and at home. Also, a bill to crack down on TikTok and potentially ban it nationwide. Plus, the new Eli Lily commercial calling out Hollywood and people who take weight loss drugs for the wrong reasons. And, daylight saving time returns and the debate over why we are still changing are clocks in the first place. 

Why are DBS' earnings coming under pressure? What do BP & UBS have in common? Find out with Michelle Martin and Ryan Huang as they break down the latest market actions.See omnystudio.com/listener for privacy information.

APAC stocks were somewhat mixed as Chinese market stabilisation efforts offset the early headwinds from Wall Street.Fed SLOOS (Q4) noted that tighter standards and weaker demand were reported.RBA kept rates unchanged at 4.35% as expected, while it reiterated that a further increase in interest rates cannot be ruled out.European equity futures indicate a higher open with Euro Stoxx 50 future +0.4% after the cash market closed flat on Monday.DXY remains at elevated levels, AUD outperforms post-RBA, USD/JPY stalled after climbing to fresh YTD highs.Looking ahead, highlights include German Industrial Orders, EZ Retail Sales, Canadian Ivey PMI, NZ Jobs data, ECB Consumer Expectations Survey, Comments from Fed's Mester, Harker, Kashkari, Collins & BoC's Macklem, Supply from Netherlands, UK & US, Earnings from BP, Infineon, UBS, BMPS, Eli Lily, Ford, GE Healthcare & Chipotle.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

European equities are mixed with outperformance in the FTSE 100, post-BP earning; US equity futures in-fitting, NQ bidDollar is marginally firmer and AUD the G10 outperformer following a “hawkish hold” at the RBABonds modestly firmer, though have been edging lower throughout the European morningCrude and XAU hold around the unchanged mark; base metals are propped up on Chinese stabilisation effortsLooking ahead, Canadian Ivey PMI, NZ Jobs data, Comments from Fed's Mester, Harker, Kashkari, Collins & BoC's Macklem, Supply from the US, Earnings from Eli Lily, Ford, GE Healthcare & Chipotle.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Tom, Andrew, & Ben discussed Israel/Iran Updates, Nvidia add new AI chips for China, Disney Earnings, Eli Lily weight loss drug approval, & bond auctions. For information on how to join the Zoom calls live each morning at 8:30 EST, visit https://www.narwhalcapital.com/blog/daily-market-briefingsPlease see disclosures:https://www.narwhalcapital.com/disclosure

In this episode of "How The F**k Did You Get That Job?" hosted by David Jaffin, the guest is none other than Ethan Braden. Ethan shares his extraordinary career journey, from his early days as a pre-med student to becoming a successful marketer in the pharmaceutical industry and, ultimately, his transition to Purdue University. The conversation delves into the art of marketing, the transformative power of storytelling, and how Ethan played a pivotal role in reshaping Purdue's brand identity in the online education sphere. Listeners will gain insights into the ever-evolving world of marketing and the importance of adaptability and mentorship in one's career. Don't miss this episode as Ethan Braden's career path serves as an inspiring example of how diverse experiences can lead to remarkable achievements in the realms of marketing and higher education. Episode Highlights 0:00 Intro  1:38 What was your dream job as a kid  3:07 What prompted your college decision  5:17 What did your first job after graduation look like  7:29 What was your first impression walking in to Eli Lily  8:17 How did you navigate between roles at Eli Lily  9:02 What was the moment where you realized you had a knack for marketing 11:05 if you were to sum up Eli Lily in one lesson what would it be  12:35 How did you know it was time to move on from pharmaceuticals  14:15 Tell me about your mentor  15:53 What made you want to come in to Purdue and do things differently   17:38 What are you doing with Purdue Global to innovate their marketing 18:33 How do you differentiate yourself from the online landscape  22:34 How do you create the alumni feeling for your global students  24:01 How do you make sure the Purdue brand is being continued and cherished  26:32 What campaign do you feel allowed you to win the AMA marketer of the year award  28:10 If you were to give your 21 year old self some advice what would it be  29:40 OpenFortune sponsorship  30:40 Quick question round  32:46 Outro 

1.Today is the 9-11 anniversary. This is often a light volume session that will often finish slightly positive. 2. This Friday is options ex for September. It is a quadruple witching options expiration. That means that four different asset classes will expire this week. It will usually make for a lot of erratic action in many different stocks. Often, stocks that are in the stratosphere will pull back and stock beaten up will often catch bids. Just expect the unexpected. 3. This morning, the semiconductors are not participating in the early tech rally. Leading semiconductor stocks such as NVIDIA and AMD are both trading lower. These stocks are also dragging the Semiconductor ETF (SMH) lower. Earlier today, Apple (AAPL) and Qualcomm (QCOM) signed a deal where QCOM will supply chips to Apple for the next 3 years. It's ironic how this news was released this week ahead of options ex. 4. There's a veritable gold rush taking place in weight loss drugs. Eli Lily and Novartis stocks are booming. Lily is up 600% since 2020. Novartis has an over $400 billion market cap. More companies are trying to replicate their success. 5. Gold is trading up a little as the US dollar Index pulls back. We always must be careful with gold this week as it is often vulnerable to institutional game playing during options expiration. 6. Bitcoin is trading down by over 2% today. This chart is not looking very good right now. I'm not seeing any strength in the daily or weekly chart and the next major support area is around the 21.500 area. Visit Nick at: https://Inthemoneystocks.comVisit FSN at: https://FInancialSurvivalNetwork.comThis show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/4295686/advertisement

Moody's boccia o mette in guardia le banche Usa. Per gli analisti, mossa tardiva, Eli Lilly e Novo in territorio record: scommettono su perdita di peso, Amazon: a ottobre secondo Prime Day, X (Twitter) vuole tornare ad attrarre inserzionisti Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode 90: Neal and Toby break down New York City's adoption of a congestion toll that would charge vehicles for driving in Manhattan, and why it could be setting a precedent for other cities around the country. They also explain why a possible weight-loss pill from Eli Lily has investors on Wall Street salivating. Plus, SCOTUS hears a case that could block plans to tax the rich. Toby gets trendy and explains why Gen-Z loves cottage cheese and why insurance companies are not pickleball fans. And finally why Jell-O Shots are taking over the.... College World Series? Listen to Morning Brew Daily Here: https://link.chtbl.com/MBD Watch Morning Brew Daily Here: https://www.youtube.com/@MorningBrewDailyShow Learn more about your ad choices. Visit megaphone.fm/adchoices

Dan Nathan, Guy Adami and Carter Worth break down the top market headlines and bring you stock market trade ideas for Monday, May 22nd 0:00 - Debt Ceiling Update 13:30 - Micron 18:00 - CBW on SOX 23:00 - CBW on Qualcomm & Intel 25:20 - Eli Lily vs Pfizer 30:40 - Coke vs Pepsi 34:20 - U.S. Dollar & Consumer Staples MRKT Call is brought to you by our presenting sponsors CME Group, FactSet & SoFi Watch MRKT Call LIVE at 1pm M-TH on YouTube Sign up for our emails Follow us on Twitter @MRKTCall Follow Dan Nathan @RiskReversal on Twitter Follow @GuyAdami on Twitter Follow @CarterBWorth on Twitter Follow us on Instagram @RiskReversalMedia Like us on Facebook @RiskReversal Watch all of our videos on YouTube

0:00 Intro 0:38 VC Dirty Money (LP Sources) 8:30 Power Dynamics Founder vs VC 12:56 Trillion $ Alzheimer's Opportunity 14:26 Eli Lily's New Alzheimer's Blockbuster (?) Donanemab 19:01 More Issues with Donanemab Phase III Results 21:48 Will Anyone Pay for Donanemab? 24:13 Donanemab Side Effects 27:15 Startup Opportunities in Alzheimer's  31:34 Outro Articles Mentioned Founders need to take a stand against VC's 'dirty money': https://sifted.eu/articles/founders-vc-dirty-money Eli Lily Donanemab Phase III Press Release: https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional Cost Effectiveness of Donanemab: https://pubmed.ncbi.nlm.nih.gov/35344024/ Podcast Links YouTube: https://www.youtube.com/@bigpicturemedicine Apple: https://podcasts.apple.com/gb/podcast/big-picture-medicine/id1500446262 Spotify: https://open.spotify.com/show/5707RPmWOJkVZyUHNRSUfS?si=96c7fff6bccb456a People Dr Imran Mahmud: https://www.imranmahmud.com/ Dr Adam Bataineh: https://twitter.com/DrAdamBat?s=20 Dr Mustafa Sultan: https://www.musty.io/

Up first, how about a bedtime story? This week it's the forgotten Story of Brownie Wise, the Ingenious Marketer Behind the Tupperware Party. Earl Tupper invented the container's seal, but it was a savvy, convention-defying entrepreneur who got the product line into the homes of housewives. Up next, King Kong calls his agent to complain about all the headlines linking him with Eli Lily's new obesity drug. Let's end today's show with a heartwarming conversation between Frank and Dolores. Last time we visited with our favorite 1950s power couple they were talking about M&Ms going woke. This week they are here to share their observations about the homelessness crisis.

Mark Pauly, Wharton Professor Emeritus of Healthcare Management, joins the show to discuss the rising costs of insulin on the heels of Eli Lily's announcement that it will cap insulin prices at $35 per month. Hosted on Acast. See acast.com/privacy for more information.

Clinical trials are essential to progress in medicine, but racial and ethnic minorities are frequently underrepresented in such studies. In this ASCO Education podcast episode, we will examine this issue with Dr. Carol Brown, gynecologic cancer surgeon and Chief Health Equity Officer at Memorial Sloan Kettering Cancer Center, Dr. Ana Maria Lopez, Professor and Vice Chair of Medical Oncology at Sidney Kimmel Medical College and former Chair of ASCO's Health Equity Committee and Mr. Ted Bebi, Innovation Manager at Medidata Solutions. They discuss how diversification of clinical trials contributes to health equity (4:03), barriers to participating in clinical trials (14:37), and what clinicians and trial sponsors can do to improve participant diversity in clinical trials (20:25).  Speaker Disclosures Dr. Carol Brown – None Ted Bebi: Employment – Medidata (a Dassault Systèmes company); Stock and Other Ownership Interest – Pfizer, Eli Lily, Abbvie, Merck, BMY        Dr. Ana Lopez - None Resources ASCO-ACCC Initiative to Increase Racial & Ethnic Diversity in Clinical Trials Journal Article: Increasing racial and ethnic diversity in cancer clinical trials Journal Article: Representation of minorities and women in oncology clinical trials Podcast: Impact of Implicit Racial Bias on Oncology Patient Care and Outcomes ASCO-ACCC JustASK Training Program If you liked this episode, please follow the show. To explore other educational content, including courses, visit education.asco.org. Contact us at education@asco.org. TRANSCRIPT Dr. Carol Brown: Welcome to the ASCO Education podcast. I'm Dr. Carol Brown, a gynecologic cancer surgeon and the Chief Health Equity Officer at Memorial Sloan Kettering Cancer Center. Our guests and I will be exploring the problems and solutions with regards to racial disparities in clinical trials.   A necessary element for conducting clinical trials is, obviously, the enrollees or participants. Racial and ethnic diverse groups are frequently underrepresented in clinical trials, despite having a disproportionate burden for certain cancers. In addition, there is increasing evidence that a person's individual genetic makeup may determine the level of toxicity or efficacy of a new cancer drug specifically. Therefore, when we don't have enough diversity in our cancer clinical trials, it can really undermine the generalizability of our results. And so, to address this gap, in its recent updated guidance to industry, the US Food and Drug Administration stated that enrollment in clinical trials should reflect the diversity of the population who ultimately use a treatment.   In 2022, ASCO and the Association of Community Cancer Centers issued a joint statement recommending that anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving equity, diversity, and inclusion.   Joining me to discuss this important topic today is Dr. Ana Maria Lopez, who's the Professor and Vice Chair of Medical Oncology at the Sidney Kimmel Medical College. And she's the former Chair of ASCO's Health Equity Committee. Our second guest is Mr. Ted Bebi, Innovation Manager at Medidata Solutions. His research explores underrepresentation of black patients at clinical trials and how diversity impacts clinical trials.  Participant disclosures for this episode are listed on the podcast page.  So why should we care about improving diversity in clinical trials? Dr. Lopez? Dr. Ana Maria Lopez: We are clinicians. We are wanting to take care of our patients as best as possible, and we can only do that if our studies include everyone. An example that I often think about is the concept of airbags began in 1953, and in 2008, the National Highway Traffic Safety Administration came out and said, “You know what? We should be testing airbags on small female crash test dummies because otherwise, we don't know that these airbags will be safe.” And in fact, there were data that the airbags that existed put women and children at a much higher risk for injury or death. So, we want to be ahead of that curve, and we want to allow the best possible treatment. Dr. Carol Brown: So, Mr. Bebi, what would you say about how we could improve diversity in clinical trials? Ted Bebi: So I really like the example of the airbags that Dr. Lopez brought up because it makes it clear when building a product it's important to test the product in a representative sample of the population that will ultimately end up using it. It's the same with products like medications. If you want an efficacious drug, you should test it in the appropriate population. It's what constitutes good science. Additionally, adequate diversity in clinical trials is also important because it's ultimately an issue of health equity and providing fair access. Dr. Carol Brown: Could you kind of go on from there and talk about, specifically, how does diversifying the group of people that participate in clinical trials actually translate into increasing health equity?  Ted Bebi: Well, participating in a clinical trial is a form of receiving health care. Often, we are talking about patients for which a clinical trial might be their last resort. And even if not, participating in a clinical trial means gaining early access to potentially life-changing drugs that could become the new industry standard and doing so at no cost. So, you're receiving care and follow-up from some of the best specialists in the field. So having fair access to this opportunity for all patients is definitely a health equity issue. Dr. Carol Brown: Great. Dr. Lopez, how would you answer that question about how does diversifying clinical trials contribute to health equity? Dr. Ana Maria Lopez: Yeah, no, I think I agree with everything that Mr. Bebi said. In addition, I think we have to remember that diversity is more than race. Race is truly a social construct. We need to think about gender. We need to think about age, the whole lifespan, and people are living longer. How we metabolize medications at different time points in our life may vary. So, lots of different factors that we can consider when we think of diversity. But the gold standard is really: Are folks getting the best outcome possible? And as long as that metric is not being reached, we need to be thinking of how can we facilitate that. Dr. Carol Brown: So, Dr. Lopez, you brought up this concept that health equity is really the best outcome possible. Could you comment a little bit about how do we know, particularly in cancer, what is the best outcome possible? So how do we determine what the reference is for that, so we can figure out whether our patients are actually getting health equity? Dr. Ana Maria Lopez: Sure. So, we use different time points. We can look at relapse rates, survival rates, and of course, part of that may be comorbidities. Certain comorbidities that people have may impact their cancer treatment outcomes. So, it is complex, but it is important for us to take a look contextually at what the patient's risk is and what the patient's outcome would be. Dr. Carol Brown: We can kind of all agree that when we're talking about equity, it's getting the best outcome for everybody, no matter what they're bringing to it. And I really like your comment, Dr. Lopez, about race being not only the only factor but remembering that it is a social construct. If you could add to that, Mr. Bebi. Ted Bebi: We're talking a lot about diversity in clinical trials in terms of race and ethnicity, and that is something that is ultimately very important. But we're talking about diversity in all sorts of aspects. We're talking about diversity with age. We're talking about diversity with sex, with socioeconomic aspects because we often use race as a proxy for other things that might be going on in patients' lives. And we need to consider all of this part of diversity in clinical trials because once the drug is out in the market, it will be an intersection of potentially all of those identities and many things going on in their life that might affect how they respond. So, when we're thinking about race as a diversity point, we might be using it as a proxy for a specific type of individual, a specific patient journey that we want to make sure to include. It's not necessarily that race is the end-all, be-all measure of diversity; it's that we want to capture the true patient experience for that disease. Dr. Ana Maria Lopez: What I think is also really interesting is how we collect the data. And some of what the last couple of years have taught us is that folks may not trust our healthcare systems, and so folks may not be willing to say, ‘I am X, Y, or Z,' which certainly puts us a little bit in the void. So how important it is for us as clinicians, as researchers, to be part of creating an environment where patients can feel that ‘Yes, I can trust and I can share, and I can say, this is who I am,' because that could impact clinical care. Dr. Carol Brown: So, acknowledging that race is a social construct and that it really is used as a surrogate for other social determinants of health and other factors that affect health, and again, really acknowledging what you said, Dr. Lopez, that even asking people to identify their race is extremely problematic. But given what we do know and what our experience has been in the clinical trial world, first, Mr. Bebi, could you comment about what has been your experience and your research with the current state of participation by diverse racial and ethnic groups in clinical trials in the United States? What have you found in your research?  Ted Bebi: Recently, at Metidata, we published a paper where we looked at the state of black participation in clinical trials. We found the level at which you look at the data really matters. For example, when we looked at racial diversity across all US trials, black representation actually matched the proportion of black people represented in the 2020 US National Census, which is about 14%. But looking deeper, there were actually huge differences by therapeutic and disease area. And specifically, we saw that in oncology, black participation was only at around 8.5%, so far below the representation of black people in the United States.   Another interesting story is that when we were looking at the central nervous system therapeutic area, overall, we saw a pretty high rate of black participation at around 20%. But when we looked at one of the largest central nervous system indications, Alzheimer's, we saw only 5% black participation, so much, much lower. What we discovered is that within this therapeutic area, there were actually a lot of psychiatric trials that were driving the rate up. So, the main takeaway from this research is that you cannot take a general level of diversity as adequate for all diseases. You really have to zoom in on the specific indication to understand what constitutes good diversity or representative diversity for that disease.  Dr. Carol Brown: I'd like to ask both of you what do you think about that - what the bar should be. Because Mr. Bebi, you mentioned using the census distribution of races in the population, but I think a lot of us in the cancer field feel like that maybe isn't the right bar. Maybe the bar should really be what is the cancer burden distributed according to self-identified race, ethnicity, or other categories. And when you look at that, I think you find some different statistics. So, Dr. Lopez, could you comment about what your work has shown you about the current state of representation of diverse people affected by cancer in cancer clinical trials, and maybe get a little bit more into what you were saying earlier about the definition of race and the challenge of determining race, etc. Dr. Ana Maria Lopez: We really need to look closely at the data, and that looking at therapeutic trials and at specific populations can be really important. Now, we're a big country, so there can be - what is the catchment area that you serve? And in that catchment area, what are the cancers you're treating, and in which populations are at greatest risk? But right, sometimes it may not be - let's say the population is 10%x, but if that population is at higher risk for a certain disease, to really get granular about the understanding, I need to recruit more people that are from that greater-risk population. So that's where I think it's so important to know the population, to have connections with the community. And actually, the community can say, “Hey, this is what you may want to be studying because this is what impacts us.” Ted Bebi: If I can speak on the research side as well, the best way to ensure representative diversity is to have a very solid understanding of the natural prevalence of a disease. We need to be able to understand what the risk populations are and, even further, what does the mortality look like? Are there differences in how different patients are experiencing the disease further on, not just how they're getting the disease and how often they're getting the disease? So it needs to look different for every single indication. And even with the oncology, for example, the two largest indications in clinical trials for oncology, lung cancer and breast cancer, they also look slightly different. With lung cancer, and our research showing at 8% black participation and breast cancer being a little bit higher at around 11%. So, we always need to take into consideration that incidents include prevalence, include mortality. And yes, the golden standard should be can we build a clinical trial that reflects the actual representative diversity of the disease in the real world? That is what we're striving for. Dr. Carol Brown: I would agree with that. I would also add, though, that there may be some specific cancers for which you want to have an even greater representation of a particular group because it might be directly related to the question you're trying to answer. So, for example, you mentioned breast cancer, so I think most of the audience is probably aware that young women who self-identify as black tend to have a higher mortality from breast cancer. And this is believed to be because they are more likely to get triple-negative breast cancer. And so one of the strategies we've looked at at our cancer center is for trials specifically for triple-negative breast cancer, trying to overrepresent women who self-identify as black or have African ancestry in those trials because we're specifically trying to make sure that we do something to narrow that gap in survival from breast cancer that they experience. So, I think that, as you all mentioned, I think what we can take from this is it's really important to look closely that there are different layers and subtleties that we have to take into account.  So, I think we've clearly established that there is underrepresentation of diverse groups. But let's talk about why. So why do we think that different self-identified races and ethnicities or age groups or socioeconomic status background people are underrepresented in clinical trials? What are some of the reasons in your experience for this, Dr. Lopez? Is it funding outreach? What are the main barriers that you've experienced in terms of getting diverse populations to participate in clinical trials? Dr. Ana Maria Lopez: Maybe all of the above. But one of the things, and one of the things that we're working on, is when a person comes in and you have the trauma of the diagnosis. And they're offered a study, and there may be suspicion of the health care system, that may not be the best time to really talk and educate around a clinical trial. So, if people receive the education, learn about clinical trials before that acute event, then they can come in more prepared. So, one is just the concepts of randomization, double blind in the setting where there may be distrust of the healthcare system may be difficult. Also, some of the clinical trials, and I'm sure everyone has studies where the person needs to be at the clinic for about 12 hours getting blood draws. And people have other responsibilities, and they may not have the support mechanisms for transportation, for childcare, for elder care. And if you're taking two to three buses and, you know, here I am in Center City, Philadelphia, and you need to take two to three buses to get home at 07:00, that could be a deterrent to getting on a clinical trial.   So, there are lots of clinical factors, social factors, experience with the studies, and also how we design the studies. Can we design studies so that we are more inclusive in the criteria? So, I think lots of questions, and then certainly there are clinician factors. There could be bias that we all have that maybe we don't offer studies to certain people, so something for us to be very introspective about as well. Dr. Carol Brown: So, Mr. Bebi, could you comment specifically on, with the research that you've done, are there some barriers on the side of the sponsors of the trials or in terms of industry that you found and that you found in your work at Medidata, maybe really affecting the ability of diverse people to participate in clinical trials? Ted Bebi: Dr. Lopez did a really good job at presenting what we consider patient-level barriers, such as mistrust in the healthcare system. Logistical issues such as taking time off from work, transportation, or feeling that the investigators running the trials don't fully represent the patient. But the industry-level barriers are just as important. A lot of companies are making decisions on what good diversity should look like and where they can find more diverse patients based on incomplete data sources such as disconnected external data, or they might be limited to data from the companies.  Dr. Carol Brown: Great. So, Dr. Lopez, what do you think individual physicians can do, or individual investigators can do to improve the diversity of representation in cancer clinical trials? Dr. Ana Maria Lopez: Certainly, being circumspect, being aware of our own biases, our own approaches. But as a health system, I think we need to think about: How can we make it easy to enroll people into trials? So are there ways, if this is, for example, a study for people at this stage of cancer, that all of those patients could be screened in the electronic record? Let's have our electronic tools work for us so that we identify patients that are meeting the study criteria and then connecting the patients, the study, and the investigators together. So, this way, by having our systems identify potential participants, there's a less chance of there being that personal bias. The research team can come to the doctor, to the oncologist, let's say, and say these are folks that are eligible. What do you think? So, in a way, setting up systems to help with the recruitment would be very helpful. Dr. Carol Brown: Mr. Bebi, can you comment from the standpoint of specifically– because you focus on this– the importance of data, the data, how to capture the data about race or ethnicity or whatever the demographic diversity variable is, what can individual investigators do to really address the challenges around collecting this data and sharing it? Ted Bebi: Often, race and ethnicity data is not even captured at all. So, if we want to understand this issue better and improve upon it, we need better data inputs in order to produce this large-scale research that will help us ultimately advance the issue and not just rely on anecdotal information. Dr. Carol Brown: Are there any technologies or things that you came across in your specific work that can help with this ability to capture this type of data and to share it? Ted Bebi: I think it has more to do with the awareness and the clinician relationship with the patient. And I also think it has to do with sponsors and the way that they design the trial, to begin with, whether or not the race and ethnicity entry is something that they're asking in their electronic health forms. Because if that is not included in the clinical trial, to begin with, then there won't be any incentive to capture that information. Dr. Carol Brown: Dr. Lopez, do you have any specific tips that you would recommend to clinicians who want to improve recruitment of underrepresented groups in their clinical trials? Dr. Ana Maria Lopez: I think one thing that's really important is to be able to have the time. Now, that may not mean that it's all the clinicians' time. It may mean that you have a research coordinator. It may mean that you have a research nurse. It may mean that you give the patient a video that explains the study that they can take home. There can be different ways. Something that I often ask a patient is, “How do you make decisions?” People tell me, “You know, I always go over this with my wife,” let's say, or, “I always discuss this in our family, and then we come to a conclusion.” Because that really helps me to think about how should I best deliver the information so that the patient can really feel I made a good decision and I made a value-congruent decision. So, I think time is critical and to set up our patient experience to really facilitate that type of experience for the patient.  Also, as a reference, I would urge people to take a look at the recent recommendations put out by ASCO and ACCC that talk specifically about increasing racial and ethnic diversity in cancer clinical trials. So, there are lots more strategies, a lot more ideas, and ways to really support clinicians and researchers. Dr. Carol Brown: Mr. Bebi, do you have any specific tips, particularly for trial sponsors, about how they can improve diversity in their clinical trials? Ted Bebi: In terms of companies and sponsors, what they can do if they want to improve diversity in their trials is they need to find and include the right sites that serve the populations that they are looking for. We published research that shows that there is high variability of diverse recruitment based on which sites you are looking at, with some sites providing the highest concentration of diverse patients. So, if diversity is not woven into trial design off the bat and you're not selecting the right sites, you run the risk of not reaching these populations. Companies also need to be willing to put in work to educate and develop sites into clinical trial sites. A clinical trial site is about building trust and relationships and knowing how to be culturally adept at talking to diverse communities.   Dr. Carol Brown: Great. Thank you so much. Well, I want to thank both of you, Dr. Lopez and Mr. Bebi, for a lively discussion on this ASCO Education podcast about diversity in clinical trials.   The ASCO Podcast is where we explore topics ranging from implementing new cancer treatments and improving patient care to oncologist well-being and professional development. If you have an idea for a topic or a guest you'd like to see on the ASCO Education Podcast, please email us at education@asco.org. To stay up to date with the latest episodes and explore other educational content, please visit education.asco.org.  Speaker Disclosures Dr. Carol Brown – None Ted Bebi: Employment – Medidata (a Dassault Systèmes company); Stock and Other Ownership Interest – Pfizer, Eli Lily, Abbvie, Merck, BMY       Dr. Ana Lopez – None The purpose of this Podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this Podcast express their own opinions, experience, and conclusions. Guest statements on the Podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

US equity markets settled modestly higher as markets digested further remarks from Federal Reserve chair Jerome Powell on the pace and duration of higher interest rate rises to fight inflation.- Dow eased -58-points or -0.18%, with Merck & Co Inc (down -2.68%) and Travelers Companies Inc (-1.44%) The broader S&P500 edged +0.14% higher, with Real Estate (up +1.32%) and Information Technology (+0.84%) offsetting falls for the Energy sector (down -1.02%). Tesla Inc fell -3.04% with the U.S. National Highway Traffic Safety Administration began investigating two complaints of steering wheels coming off 2023 Model Y vehicles while vehicle was in motion. Occidental Petroleum Inc gained +2.14% after a new regulatory filing showed Warren Buffett's Berkshire Hathaway added to its already large stake in the company. The Omaha-based conglomerate bought nearly 5.8M shares of the oil company in recent sessions, bumping Berkshire's ownership to 22.2%. Eli Lily and Co fell ~0.45% in extended trading (after rising +0.61% in the regular session) after the Wall Street Journal reported that the company's drug aimed at preventing Alzheimer's disease before symptoms start, solanezumab, had failed to slow down cognitive decline in healthy older adults at risk of developing the disease. The Nasdaq added +0.40%. The small capitalisation Russell 2000 inched +0.04% higher. Uber Technologies Inc rose +2.15% after Bloomberg reported that the company is weighing a potential spinoff of its freight logistics unit.

US equity markets settled modestly higher as markets digested further remarks from Federal Reserve chair Jerome Powell on the pace and duration of higher interest rate rises to fight inflation.- Dow eased -58-points or -0.18%, with Merck & Co Inc (down -2.68%) and Travelers Companies Inc (-1.44%) The broader S&P500 edged +0.14% higher, with Real Estate (up +1.32%) and Information Technology (+0.84%) offsetting falls for the Energy sector (down -1.02%). Tesla Inc fell -3.04% with the U.S. National Highway Traffic Safety Administration began investigating two complaints of steering wheels coming off 2023 Model Y vehicles while vehicle was in motion. Occidental Petroleum Inc gained +2.14% after a new regulatory filing showed Warren Buffett's Berkshire Hathaway added to its already large stake in the company. The Omaha-based conglomerate bought nearly 5.8M shares of the oil company in recent sessions, bumping Berkshire's ownership to 22.2%. Eli Lily and Co fell ~0.45% in extended trading (after rising +0.61% in the regular session) after the Wall Street Journal reported that the company's drug aimed at preventing Alzheimer's disease before symptoms start, solanezumab, had failed to slow down cognitive decline in healthy older adults at risk of developing the disease. The Nasdaq added +0.40%. The small capitalisation Russell 2000 inched +0.04% higher. Uber Technologies Inc rose +2.15% after Bloomberg reported that the company is weighing a potential spinoff of its freight logistics unit.

Krystal and Saagar discuss the Republican civil war over East Palestine Aid, Corporate media caught running Railroad propaganda, Trump surging in all Republican 2024 polls, Fox stunned as Diner voters back Trump over Desantis, Saagar presses Vivek Ramaswamy on his 2024 run, Insulin company Eli Lily cuts insulin prices, the Havana Syndrome is debunked, China threatens Elon Musk over Lab leak tweets, Krystal looks into Fake Media Mogul at Ozy media is arrested for fraud, Saagar looks into the comparisons between Iraq WMD's and Lab Leak, and Branko Marcetic (@BMarchetich) from Jacobin joins us to talk about the media's lies on Ukranian democracy.To become a Breaking Points Premium Member and watch/listen to the show uncut and 1 hour early visit: https://breakingpoints.supercast.com/To listen to Breaking Points as a podcast, check them out on Apple and SpotifyApple: https://podcasts.apple.com/us/podcast/breaking-points-with-krystal-and-saagar/id1570045623 Spotify: https://open.spotify.com/show/4Kbsy61zJSzPxNZZ3PKbXl Merch: https://breaking-points.myshopify.com/ Learn more about your ad choices. Visit megaphone.fm/adchoicesSee omnystudio.com/listener for privacy information.

Krystal and Saagar discuss the Republican civil war over East Palestine Aid, Corporate media caught running Railroad propaganda, Trump surging in all Republican 2024 polls, Fox stunned as Diner voters back Trump over Desantis, Saagar presses Vivek Ramaswamy on his 2024 run, Insulin company Eli Lily cuts insulin prices, the Havana Syndrome is debunked, China threatens Elon Musk over Lab leak tweets, Krystal looks into Fake Media Mogul at Ozy media is arrested for fraud, Saagar looks into the comparisons between Iraq WMD's and Lab Leak, and Branko Marcetic (@BMarchetich) from Jacobin joins us to talk about the media's lies on Ukranian democracy. To become a Breaking Points Premium Member and watch/listen to the show uncut and 1 hour early visit: https://breakingpoints.supercast.com/ To listen to Breaking Points as a podcast, check them out on Apple and Spotify Apple: https://podcasts.apple.com/us/podcast/breaking-points-with-krystal-and-saagar/id1570045623   Spotify: https://open.spotify.com/show/4Kbsy61zJSzPxNZZ3PKbXl   Merch: https://breaking-points.myshopify.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

TikTok changes, Eli Lily cuts insulin cost, explosive found in bag at Pennsylvania airport, incoming winter storms, new Ed Sheeran album details, Chris Pine addresses SpitGate, Travis Scott is under investigation, Prince Harry and Megan evicted, Elvis movies streaming and new Elvis cartoon coming soon, Hoda Kotb's absence addressed & more... Learn more about your ad choices. Visit megaphone.fm/adchoices

Senator Bernie Sanders, chairman of the senate, health committee, scares companies into lowering or eliminating prices.  SPONSOR: AdamAndEve.Com USE OFFER CODE: DEWEY AT CHECK-OUT FOR 50% OFF OF ALMOST ANY ONE ITEM AND FREE SHIPPING! SPONSOR: AdamMale.Com USE OFFER CODE: DEWEY AT CHECK-OUT FOR 50% OFF OF ALMOST ANY ONE ITEM & FREE/DISCREET SHIPPING! SPONSOR: https://dshow.link/popl Popl (digital business card) Popl works by allowing you to instantly share contact information. By tapping your phone to the Popl, a push notification appears on the other person's phone which will take them straight to your Popl profile with all of your links. The great part is, the other person does not need a Popl or an app for this to work! 25% off ⬇️ SPONSOR: https://dshow.link/popl ENTER CODE Dewey AT CHECKOUT LINKS MENTIONED ON DSP: ——————————————————————————— ALL OF The Dewey show™ LINKS: https://dshow.link/Links The Dewey show network™ : www.dews.news Join The Dewey show™ Patreon!: https://dshow.link/join MAKE A ONE TIME DONATION TO THE SHOW: CASH APP: https://dshow.link/1x DONOR BOX: https://dshow.link/Db STORE: https://dshow.link/store SOCIAL MEDIA: Twitter: https://dshow.link/Twitter Facebook: https://dshow.link/YkCyJA Personal Instagram: https://dshow.link/Ig Podcast Instagram: https://dshow.link/PodIG TikTok: https://dshow.link/TikTok CONTACT:  deweyshow@aol.com https://dshow.link/email

TikTok changes, Eli Lily cuts insulin cost, explosive found in bag at Pennsylvania airport, incoming winter storms, new Ed Sheeran album details, Chris Pine addresses SpitGate, Travis Scott is under investigation, Prince Harry and Megan evicted, Elvis movies streaming and new Elvis cartoon coming soon, Hoda Kotb's absence addressed & more... Learn more about your ad choices. Visit megaphone.fm/adchoices

23-11-2022Noticia Twitter: Nueva verificación check azul- A partir del 29 de noviembre de 2022- Elon Musk- Problemas previos- 8$/mes- Twitter Blue- Estados Unidos, Canadá, Australia y Nueva Zelanda. - Ya no se puede cambiar el nombre si te verificas o pierdes el check azul- Caso farmacéutica Eli Lily caída en bolsa por cuenta falsa verificada dijera insulina gratis. - Audi, General Motors o Volkswagen suspendían sus campañas de publicidad en Twitter.Recuerda suscribirte al podcast para no perderte el resto de noticias, novedades, trucos y tendencias del Marketing Digital y las Redes Sociales. Si te ha gustado comparte el episodio, dale a me gusta, deja 5 estrellas o comenta el episodio. Me ayudarás a seguir creando episodios completamente gratis y no tener que cobrar por ellos.Grupo Telegram: https://borjagiron.com/telegramTambién puedes acceder completamente gratis a todos mis curso de Marketing Digital desde https://triunfacontublog.com Soy Borja Girón, has escuchado el podcast Marketing Digital, nos escuchamos en el próximo episodio.

23-11-2022Noticia Twitter: Nueva verificación check azul- A partir del 29 de noviembre de 2022- Elon Musk- Problemas previos- 8$/mes- Twitter Blue- Estados Unidos, Canadá, Australia y Nueva Zelanda. - Ya no se puede cambiar el nombre si te verificas o pierdes el check azul- Caso farmacéutica Eli Lily caída en bolsa por cuenta falsa verificada dijera insulina gratis. - Audi, General Motors o Volkswagen suspendían sus campañas de publicidad en Twitter.Recuerda suscribirte al podcast para no perderte el resto de noticias, novedades, trucos y tendencias del Marketing Digital y las Redes Sociales. Si te ha gustado comparte el episodio, dale a me gusta, deja 5 estrellas o comenta el episodio. Me ayudarás a seguir creando episodios completamente gratis y no tener que cobrar por ellos.Grupo Telegram: https://borjagiron.com/telegramTambién puedes acceder completamente gratis a todos mis curso de Marketing Digital desde https://triunfacontublog.com Soy Borja Girón, has escuchado el podcast Marketing Digital, nos escuchamos en el próximo episodio.

Die heutige Folge ist eine einzige Content und Trigger Warnung. Wir fräsen uns durch Social Media und prophezeihen das Ende dieses Sündenpfuhls. Dabei lassen wir kein aktuelles Thema aus und streifen Elons Twitter-Shit-Show, Cathy Hummels bunte Welt der Depressionen, Verena Bahlsens Surfurlaub, 16 Milliarden Verlust bei Eli Lily, dreckige Beziehungswäsche bei Instagram und einzig die Dunbar-Zahl hilft uns, wenigstens ansatzweise einen wissenschaftlichen Anschein zu wahren.

The guys are broken up over the loss of childhood hero Aaron Carter and comedic genius Gallagher. The good news is that Eli Lily lost billions in the most hilarious way possible, and cryptocurrency proves yet again why it can only be believed in by the bros.

Trendspider's sale ends 11/18 - CLICK HERE I was asked after the podcast ended which stocks I would trade today - there are 2 - $BABA for a potential earnings pop (gambling IMO) or $TGT for their earnings and gap fill. You won't mind holding $TGT if they don't report something outstanding. Berkshire dumping Bancorp and took tsm stake along with paramount holdings $para Sold 5% of $gm shares $ZM for Thomas - earnings Monday Jackson from insta Did you see the Chaos with Eli Lily & Lockhead Martin last week with the fake twitter accounts effecting the stocks? Interesting those ones haven't really recovered after that… anonymous Hey just a little insight, on Saturday I bartended at US C for professors that they brought around from all over the world that teach social entrepreneurship. I was speaking to one guy in particular who used to trade derivatives for a living, particularly futures. He's now a professor teaching in Boulder. Anyways I've asked for his opinion on the CPI data and how long he thinks this rally will be lasing. I said that I believe it'll last for a couple weeks he believes the CPI data will have this rally lasting a couple months. Anyways, I thought that information you might find useful or at least insightful. Least I can do for the tips and help you have given me $Shls huge move on earnings $Nflx booming on $bac upgrade $Hd missed based on customer transactions down 4.3% even though revs beat but didn't increase guidance - $LOW is the buy $Nvda earnings from weekly stock pick $WMT big beat and $20b share repurchase - crazy good quarter - inventory levels under control - they are seeing consumers having less to spend on ancillary items but they are seeing people buying on holiday sales $TGT and $COST Much higher sales from people with salaries over $100k which indicates even rich folk like me are moving to shopping at Walmart $Hd recovered after Walmart earnings From Tom $Imgn-- successful treatment ovarian cancer very good results in trial released after hours yesterday. It will explode todwy $SOXL $BABA $aapl looking to get in to the metaverse based on job postings Shoutout ups man on Instagram - he listens while he drives and I made the joke “what brown can do for you” SCANS $QS $CEG $TSLA - under $200 - CHRIS - brought up $TSLL Support the podcast - https://anchor.fm/dailystockpick/support Social Links and more - https://linktr.ee/dailystockpick --- Support this podcast: https://anchor.fm/dailystockpick/support

This is part of a 2-part series including City Council member interviews where we continue to learn about the way city government is actually run and all about the people who help make it all happen! Part 2:Sarah&Renee interview a couple of newbies... and these two men get down to business in very different ways. Mike Shaffer was appointed to serve on Fostoria City Council in 2022 representing the Second Ward. He's been with The University of Findlay and Marathon Petroleum Corporation, and he's currently employed by Eli Lily & Co. He's been a resident of Fostoria nearly all his life, and he brings all the hometown feels during his time with the girls in this interview.Don Mennel was the fourth generation president of the Mennel Milling Company. He is a regimented business man and he brings those kinds of tactics and tenacity to the way he supports his constituents in his role as a city councilman.  He says exactly what he means... are you ready for it?We learned some new things in the recording of this episode and we're curious if you do, too!

Alan Burd é formado em Administração e começou sua carreira estagiando na Unilever, onde atuou em várias áreas e aprendeu desde processos de inovação até marketing e posicionamento de marca. Sempre teve o sonho de abrir novos horizontes e para isso, realizou um intercâmbio, período no qual cursou um MBA. Durante o curso, desenvolveu aspectos importantes na Academia, na vida e no encaminhamento de carreira. Voltando ao Brasil, trabalhou na Janssen e em seguida na Eli Lily and Company como Product Manager liderando a equipe de vendas. Depois surgiu a oportunidade de integrar o time da Roche, que o encantou desde o primeiro momento. Hoje, após aceitar o desafio de fazer parte da equipe, Alan é Head de Transformação da empresa.

Woman Empowerment, Lifestyle and how to become a Lady Boss. Hey Beauties, on this week's podcast, I have the pleasure of interviewing none other than Allergan Aesthetics Senior Vice President of US Brands, Edrice Simmons. Simmons started her career at Eli Lily; an Internation pharmaceutical company worth $24 billion. Simmons has received countless awards, multiple performance-based promotions, and exceptional contributions throughout her time at Eli Lilly. Simmons then moved on to AbbVie as a Senior Marketing Director of Immunology where 5 years later she became senior VP of US Brands. We take a deep dive into how Edrice got to where she is today and discuss more on lifestyles, habits, and how we can better ourselves to become the best version of ourselves we can be. Listen in to find out more about Edrice and how to be a boss babe. Click Here to check out my Instagram! Click Here to check out my skincare products! Click Here to listen to more podcasts!

Hoy hablamos de complejos: todo el mundo tiene inseguridades en su físico: unos la calvicie, otros por su apariencia, por su nariz, por las orejas... ¿Tienes algún complejo o lo has tenido y has puesto solución? Hoy una profesional nos habla de una vacuna contra la calvicie aprobada por la FDA que será la alegría de muchas personas. En Buenos Días América arrancamos contando “Que paso mientras Ud. dormía” nuestro boletín informativo con un resumen de las noticias más importantes del día. Nelson Rauda, periodista, habla sobre Bukele pide "paciencia" a los salvadoreños ante la pronunciada caída del bitcoin. El Dr. Mejía Torres habla sobre el olvido de nombres propios y errores infantiles en adultos. Qué pasa en la mente cuando olvidas el nombre de personas conocidas. El lenguaje mudo del cuerpo. La Dermatóloga Doctora Mariela Cogorno, nos comenta acerca de la Alopecia severa: FDA aprueba la primera pastilla para restituir el cabelloEl fármaco de Eli Lily impide que el sistema inmune ataque los folículos capilares y ofrece esperanza a casi 7 millones de personas que sufren de esta condición en EEUU. Y en Contacto Deportivo, hablamos con Aldo Sánchez dando una ronda por la jornada de juego de las estrellas de la MLB, lo que pasó en el Mundial de Atletismo y la venta de boletos en Catar 2022 Mañana más, en Buenos Días América, no olvides en conectarte. Si te gusto, recuerda compartir con tus amigos que pueden encontrarnos en la App de UFORIA o en cualquier plataforma de podcast. Envíanos tus comentarios, inquietudes o sugerencias, a nuestras redes sociales en Facebook @buenosdiasam, Instagram buenosdiasamericaam o escríbenos a nfoudradio@UNIVISION.NET estaríamos encantados de recibirlas.

Two NIH researchers—Dr. Sarah A. Rudzinskas and Sarah Spector—on studies they are helping conduct for a new drug aimed at helping women in midlife who suffer from depression-typically for the first time in their lives. An estimated 20% of American women have depression at some point during menopause; and 38% experience depression in late menopause. The researchers are exploring the link between low levels of estrogen and how it impacts the brain—which this new drug, manufactured by the pharmaceutical company Eli Lily,  addresses.   Women interested in being part of the NIH study can click here for more information.  

World-renowned physician, venture capitalist and prolific entrepreneur, John Simpson, MD, rejoins Andrew Cleeland to discuss the impact he's had on the future generation of medtech innovators. Credited with inventing and commercializing the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA) and helping to create the field of interventional cardiology, John also founded and successfully exited numerous companies, including Advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI), which were both acquired by Eli Lily; CVIS, acquired by Boston Scientific; Perclose, sold to Abbott; LuMend, acquired by Cordis Corporation; and Fox Hollow, acquired by ev3, which is now part of Medtronic. Today, he continues to innovate in his work as a senior advisor to Cordis-X.

A husband, father, world-renowned physician, venture capitalist and prolific entrepreneur, John Simpson, MD, has helped revolutionize the field of cardiology via his innovations.   Credited with inventing and commercializing the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA) and helping to create the field of interventional cardiology, John also founded and successfully exited numerous companies, including Advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI), which were both acquired by Eli Lily; CVIS, acquired by Boston Scientific; Perclose, sold to Abbott; LuMend, acquired by Cordis Corporation; and Fox Hollow, acquired by ev3, which is now part of Medtronic. Today, he continues to innovate in his work as a senior advisor to Cordis-X. Andrew Cleeland had the pleasure of chatting with John to learn more about his career as a serial entrepreneur as well as his insights on what it takes to drive innovation.  

Meredith Munger Stowers (formerly Leyva) helps people achieve their goals. Stowers currently handles marketing and business development at CrossCountry Mortgage and ADUlonas.net with a focus on helping families, buy, build, renovate and refinance property, notably Accessory Dwelling Units, (ADUs). She operates ADUloans.net and serves as a founding member of the ADU Coalition, an advocate for attainable housing.  She recently wrapped up her nationally syndicated column, "The Marketing Coach" in the Business Journals. Previously, Stowers served as Chief Operating Officer for Voices Heard Media, the leading social media applications and consulting company serving clients including Disney and Scripts Networks. Before that, Stowers served as a consultant to Military.com/Monster.com after that company acquired her online community and magazine, CinCHouse.com, where she was CEO and editor. She is the author of "Married to the Military: A Survival Guide for Military Wives, Girlfriends and Women in Uniform" (Simon & Schuster, July 2003 and 2008). Her editorials and news articles have been syndicated to over 140 military base newspapers worldwide, and she has been a contributor to Army Times Newspapers, the USO's "On Patrol" magazine, Military.com and other military publications. Meredith regularly represented CinCHouse.com in the national press, including feature stories on CNN, Fox and NPR. Her work with CinCHouse has also been featured in such publications as USA Today, the Washington Times and Joint Forces Quarterly.  As part of her work on CinCHouse.com, Meredith founded Operation Homefront which is now the fifth largest charity serving military families.  Previously Meredith worked as a public relations consultant and lobbyist for a variety of companies including CareerBuilder.com, Boeing, Eli Lily, Motorola and Iridium. Meredith also served as director of Public Relations for the American Enterprise Institute and legislative assistant to Senator Jon Kyl (R-AZ). She served on the National Advisory Board of the Independent Women's Forum which published her 2001 book on Social Security reform entitled "Women and Retirement Security."The Norris Group originates and services loans in California and Florida under California DRE License 01219911, Florida Mortgage Lender License 1577, and NMLS License 1623669.  For more information on hard money lending, go www.thenorrisgroup.com and click the Hard Money tab.Video LinkRadio Show

Meredith Munger Stowers (formerly Leyva) helps people achieve their goals. Stowers currently handles marketing and business development at CrossCountry Mortgage and ADUlonas.net with a focus on helping families, buy, build, renovate and refinance property, notably Accessory Dwelling Units, (ADUs). She operates ADUloans.net and serves as a founding member of the ADU Coalition, an advocate for attainable housing.  She recently wrapped up her nationally syndicated column, "The Marketing Coach" in the Business Journals. Previously, Stowers served as Chief Operating Officer for Voices Heard Media, the leading social media applications and consulting company serving clients including Disney and Scripts Networks. Before that, Stowers served as a consultant to Military.com/Monster.com after that company acquired her online community and magazine, CinCHouse.com, where she was CEO and editor. She is the author of "Married to the Military: A Survival Guide for Military Wives, Girlfriends and Women in Uniform" (Simon & Schuster, July 2003 and 2008). Her editorials and news articles have been syndicated to over 140 military base newspapers worldwide, and she has been a contributor to Army Times Newspapers, the USO's "On Patrol" magazine, Military.com and other military publications. Meredith regularly represented CinCHouse.com in the national press, including feature stories on CNN, Fox and NPR. Her work with CinCHouse has also been featured in such publications as USA Today, the Washington Times and Joint Forces Quarterly.  As part of her work on CinCHouse.com, Meredith founded Operation Homefront which is now the fifth largest charity serving military families.  Previously Meredith worked as a public relations consultant and lobbyist for a variety of companies including CareerBuilder.com, Boeing, Eli Lily, Motorola and Iridium. Meredith also served as director of Public Relations for the American Enterprise Institute and legislative assistant to Senator Jon Kyl (R-AZ). She served on the National Advisory Board of the Independent Women's Forum which published her 2001 book on Social Security reform entitled "Women and Retirement Security."The Norris Group originates and services loans in California and Florida under California DRE License 01219911, Florida Mortgage Lender License 1577, and NMLS License 1623669.  For more information on hard money lending, go www.thenorrisgroup.com and click the Hard Money tab.Video LinkRadio Show

We are back for another great interview, today with Andrew Embry, a brand manager -- plus a wordsmith, poet. and creative alchemist.  Andrew combines spoken word & poetry with his data research and marketing roles at https://www.lilly.com/ (Eli Lilly and Company. ) Listen to the entire podcast to hear Andrews poem “bringing love into work” starting at 15:47 Andrew has been writing and performing poetry since he was a child. He has managed to not only use poetry skills offstage but also bringing these skills to work too where he has performed in front of 1000 of his colleagues.    He is an avid reader of books, blogs, and watcher of films to keep his creative juice flowing. One of those books is https://www.amazon.com/Radical-Candor-Kim-Scott/dp/B01KTIEFEE (Radical Candor) by Kim Scott. The book focuses on the importance of giving quality, direct feedback to individuals, which has enabled him to give and receive feedback better. Andrew says, if you can help people see how they're using their own style of creativity, then they can see how much that's valued and they can lean into who they are and bring even more value to you and your team. Andrew has been writing his blog Striking Matches since Jube 2013, and he gives us pointers on how he has been able to get creative ideas over the past 9 years to keep writing. The way he has done this is by having a creative mindset-believing that there is a story and hidden beauty inside everything.  Looking at the world (experiences) as your oyster. A few ideas on how to bring creativity to work especially in remote settings or working from home can include: getting up and taking walks, working out in the morning, or even taking breaks during the day just to go play with your kids. As part of the brand management team, you can bring creativity in your solutions by being empathetic to your customers' needs, while at the same time using the data you collect to make heart-level decisions when telling stories. Andrews Blog: https://andrewembry.home.blog/ (Striking Matches) Youtube: https://www.youtube.com/watch?v=jT_OaYqOaP0 (Andrews performance at Eli Lily's 140th anniversary) Company Website:https://www.lilly.com/ (Eli Lily & Company) Kim Scott's book: https://www.amazon.com/Radical-Candor-Kim-Scott/dp/B01KTIEFEE (Radical Candor) Summary. The future of marketing will be more innovative in the digital space, as we focus on meeting customers at their point of need.   We need to know how to use machine learning to help turn data into insights that we can use to be better.  Listen to the entire podcast to hear Andrews poem “bringing love into work”

649: Synaptic Alchemy , Steven Cardinale, SynapticAlchemy.com Synaptic Alchemy Steven Cardinale, SynapticAlchemy.com – The Sharkpreneur podcast with Seth Greene Episode 649 Steven Cardinale Business has always fascinated Steven Cardinale. Having to make decisions under uncertainty with limited data piqued his curiosity. Being involved in entrepreneurial ventures, startups, large Fortune 500 product development teams and C-Suite strategy sessions has given Steven the perspective to combine different thought processes to move ideas forward. Studying Economics at UCLA to earning an MBA from the Wharton School of Business, to working with some of the largest organizations around, such as Eli Lily, Janus Funds, IBM, PwC, and the J. Paul Getty Museum, to founding, operating, and successfully navigating the M&A exit process for his own SaaS company has given Steven insights from every angle of the success and innovation spectrum. Listen to this illuminating Sharkpreneur episode with Steven Cardinale about his book, Synaptic Alchemy. Here are some of the beneficial topics covered on this week's show: ● How there are three separate segments to owning a company and what they are. ● How owning a business is never about you, it's about pleasing the customers. ● Why entrepreneurs need to understand themselves to start and grow a company. ● How creating something requires business owners to destroy something first. ● Why entrepreneurs have to know how they express themselves to the world. Connect with Steven: Guest Contact Info Twitter @scardinale Instagram @synapticalchemy Facebook facebook.com/synapticalchemy LinkedIn linkedin.com/in/stevencardinale Links Mentioned: synapticalchemy.com Learn more about your ad choices. Visit megaphone.fm/adchoices

(originally aired 6.10.17)In this episode of Vitality Radio Podcast, Jared discusses the madness surrounding the early days of CBD and the fight to make it illegal to protect the drug cartels, you know; Johnson and Johnson, Eli Lily, Pfizer, Merck, etc. Jared also interviews Stuart Tomc on the latest research that shows how effective CBD can be for pain, anxiety and depression. Stuart is a leading expert in the field of CBD and hemp education. You can follow us at @vitalityradio on Instagram, Facebook and Twitter. Check us out online at vitalitynutrition.com. Let us know your thoughts about this episode by using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Just a reminder that this podcast is for educational purposes only. The podcast has not been evaluated by the FDA. The information within is not intended to diagnose, treat, cure or prevent any disease. Advice given is not intended to replace the advice of your medical professional.

Long-time state and community leader, Nate Miles, VP of Strategic Initiatives for Eli Lily, joined the program to discussed the state of our state and city, how we can work together to build the common good. See omnystudio.com/listener for privacy information.

Making decisions under uncertainty is what attracted Steven Cardinale to entrepreneurship. Being involved with startups, leading Fortune 500 teams at Eli Lily, Janus Funds, & IBM, earning an MBA from Wharton, and founding, operating and existing his own SaaS company has given Steven a unique perspective to create successful ideas “a better question is more important than the right answer. Because the right answer to the wrong question. So constantly, constantly, constantly ask questions of yourself. Once you think I've got an idea, an entrepreneurial idea then the question you need to ask is look outside of yourself and go will my customers care? And then I have to look outside that and go if my customers do care, great, how do I get to them? It's always asking better questions; it's never having an answer… So, forcing yourself to have a better question… I do this when I get people who are interested in having me invest. I listen for them asking me better questions rather than telling me they've got the answer. So, ask a better question is the vital component of becoming a successful entrepreneur”…[Listen for More] Click Here for Show Notes To Listen or to Get the Show Notes go to https://wp.me/p6Tf4b-lvg

Amazon is facing accusations in Europe as the EU moves to open a new investigation into the e-commerce giant over violations of antitrust laws. Meanwhile, developments of Covid-19 treatments continue to roll in as the FDA approves a major antibody treatment by Eli Lily while the European Commission signs a deal to secure millions of doses of the experimental drug produced by Pfizer and BioNTech.

November 10, 2020 - Daily NewsSupport the show (https://www.patreon.com/theoneminutenews)

He's known as the Man of a Thousand Jobs and he's done it all.  From horse farming and training, to security at Rupp Arena, to using dynamite to blow up mines, to analytical chemistry and everything in between.  Kevin currently works at Eli Lilly and Company and his path to Power BI was anything but a typical data journey.  He's a fine Southern Gentleman with a mind for data, he's Kevin Overstreet.   Episode Timeline: 2:07 - Kevin's Data Salvation, his impressive pedigree, and his amazing career path 9:17 - Data challenges at Eli Lily and how they've overcome them using the right tools 19:11 - The Wild West that is Sharepoint 24:00 - Rob launches one of his World Famous Monologues, this time it's about new branding for BI 30:13 - Does solving a problem have to be complex? Kevin discusses a great work mindset to overcome certain obstacles 33:00 - The Impostor Syndrome 36:30 - Dataflows and how to keep data secure 39:45 - Whose problem is it-The Business side or the IT side? 45:30 - The Power of the new BI Tools 48:36 - The story of how Kevin met Rob reveals a character trait that is valuable

Welcome to Majority.FM's AM QUICKIE! Brought to you by justcoffee.coop TODAY'S HEADLINES: Supreme Court Nominee Amy Coney Barret was confirmed by the Senate on Monday night after the GOP pushed forward a rushed full-floor vote. Meanwhile, the coronavirus is surging in multiple states, which could mean new lockdowns are coming. And lastly, another huge win for progress in South America, as Chile voted to finally abandon it’s dictator-era constitution that has been in place since a U.S.-backed coup installed right wing mass murderer Augusto Pinochet in power nearly 50 years ago. THESE ARE THE STORIES YOU NEED TO KNOW: We have a new justice on the Supreme Court. After a blitzkreig confirmation process and a hasty swearing-in ceremony, Mitch McConnell and Donald Trump successfully installed Amy Coney Barrett on the Supreme Court on Monday night. The Senate voted 52-48. Every Democrat, Independent, and Republican Susan Collins of Maine voted against Barrett, but it did nothing to Mitch McConnell’s ironclad majority. After the vote, the White House put together a slapdash swearing-in ceremony on the South Lawn to get Barrett on the bench as fast as possible. It’s hard to fully grasp what this news means. Some of the first cases Barrett sees will be related to elections in North Carolina and Pennsylvania, and she could also be part of a ruling if election results next week get challenged. If Trump does try to steal the election with the courts, Brett Kavanaugh and ACB will likely be solid votes in his favor, further bolstering the conservatives’ 6-3 majority even if Chief Justice John Roberts decides to flip and, you know, not do fascism. A strong indication that this is exactly what would go down: earlier today the Supreme Court ruled that Wisconsin would not have to continue counting absentee ballots that were postmarked by election day but arrived late, setting up a strong precedent for throwing out votes all over the place. And even if Biden does manage to take power, Barrett might be able to rule on a case that pertains to Roe V. Wade before he’s even in office. Meanwhile, the Democrats still, STILL seem fully opposed to fighting back in any way or taking steps toward reform. Earlier today, Joe Biden told reporters that he wouldn’t consider term limits for SCOTUS members. Quote “It’s a lifetime appointment. I’m not going to attempt to change that at all.” Endquote. There you have it. Coronavirus Once Again Surging Meanwhile, the coronavirus pandemic is starting to pick up steam again. Yesterday we mentioned that spikes in cases in Utah were so severe hospital administrators were preparing to ration care. Texas’s total cases have now surpassed California, with more than 910,000 total. The number of new cases in those states have increased by 19 percent and 15 percent respectively. Cases elsewhere nationwide are also climbing. In Europe, which is seeing similar spikes, many countries are preparing for a second wave of lockdowns and travel restrictions, which are basically the only way left to get a handle on the increases. But it’s unlikely that the U.S. will enact policies like that with Trump in power, and if we did, the fact that no new aid is on the way from the government means that people are going to suffer massively either way. Some state governors are doing what they can. Idaho, for instance, is preparing to enact new restrictions to grapple with a spike. But if you remember from yesterday, the Trump administration has publicly said it’s not going to try to control the disease anymore, instead focusing on cures and vaccines. The problem is those aren’t going so well either: the drug maker Eli Lily said on Monday that it’s antibody treatment does not work on patients with advanced COVID-19, and that its government sponsored trial would not be giving the drug to new patients. That’s just one treatment, of course, but it seems clear that we’re a lot further from a stable cure or vaccine than the President wants us to think. Chile Chucks Constitution Outside of the country, however, there is some good news. Voters in Chile overwhelmingly rejected the country’s outdated, repressive constitution, which had been in place since a U.S.-backed right-wing coup installed Augusto Pinochet as leader of the country. The fact that Pinochet’s constitution was still the binding legal document of the country 50 years later is surreal, and finally, after months of protests, the Chilean people had their voices heard. They voted by a massive 4 to 1 margin to approve the creation of a new constitution. Catalina Miranda, a Chilean who was among the crowd of thousands celebrating the result in Santiago’s Plaza Italia, told the Guardian quote: “We’ve been living under an illegitimate constitution created by a military regime, that’s only allowed progress to those who have money. There’s been very few times that Chilean people have shared a collective victory like today.” Endquote. Sounds uh... oddly familiar! Perhaps, especially given the travesty of governing that we’ve seen out of the Senate GOP and Trump administration, Americans could take a few notes on throwing out their Constitution and making something better. AND NOW FOR SOME QUICKER QUICKIES: In an interview with Fox and Friends on Monday, Jared Kushner gave the racism dial a good old crank by questioning whether or not Black Americans quote “want to be successful,” after claiming that his father in law had done so much for them. Also on Monday, Trump imposed a new set of sweeping economic sanctions on Iran’s oil sector, seeking to kneecap any future foreign relations a Biden administration would have with the country and ratchet up tension further before the election. Sources told the Washington Post that state and federal antitrust charges against Facebook could come as soon as November, which would be a major step toward breaking the social network’s stranglehold over almost every facet of American life. And finally, Charles Beckham III, a candidate for State Senate in Arkansas, was expelled from high school because he wore a KKK outfit on Halloween. He should probably be expelled from politics as well! That’s it for the Majority Report’s AM Quickie today. Stay tuned for the full show with Sam later this afternoon! OCT 27, 2020 - AM QUICKIE HOSTS - Sam Seder & Lucie Steiner WRITER - Jack Crosbie PRODUCER - Dorsey Shaw EXECUTIVE PRODUCER - Brendan Finn

Os desafios de ser uma CFO mulher, a importância da diversidade para as corporações e o papel das empresas no fomento de uma cultura voltada à diversidade e à inclusão estão entre os temas que comentados neste CFO Topics, com Helena Pecora, CFO da Eli Lily no Brasil, Maurício Rodrigues, CFO da Bayer Crop Science e Vera Bermudo, Conselheira da Unimed e ex-CFO da Pernambucanas. Ouça na íntegra!

On this edition of the podcast you’ll hear the latest on Hammond student-athletes returning to fall contact sports following an August cancellation due to the coronavirus pandemic, Samantha Horton reports Eli Lily says it’s COVID-19 antibody drug is showing results in reducing hospitalizations from the virus and Chris Nolte has a conversation with NWI financial advisor Greg Hammer. He offers tips to reduce “pandemic panic” while planning for retirement. All of that, and more, on this edition of “Lakeshore Update”…

Stacey Simms is all about connections and community. We met through the alumni association of our college radio station, and since her son's diagnosis of Type 1 Diabetes, she has formed an incredible community of patients and caregivers around this disease. This includes her podcast, Diabetes Connections, and her book The World's Worst Diabetes Mom.We spend a couple minutes on diabetes itself, including Stacey explaining some common misconceptions about the disease.Her podcast has connected her with everyone from diabetic celebrities to major drug companies, and she tells a great story of asking the head of Eli Lily, on a conference call, to drop the price of insulin.As a dyed-in-the-wool reporter, Stacey knew she needed an angle and focus for her podcast - and that's why she spends a lot of time focusing on diabetes news, even if that's not how the first few episodes went.Then, we delve into how Stacey started selling ads on her podcast. She stresses the importance of selling based on shows, not download numbers, as those metrics can vary wildly.   Also, in the medical field, there are a number of rules that must be adhered to when it comes to advertising copy.  Stacey explains how she navigates each of these, and also how important it is to be transparent about sponsorship dollars and what parts of the show are paid for.We zoom out, and I ask Stacey for some general advice about how -and when - to seek out advertisers for your podcast.Finally, I ask Stacey for advice for other diabetes parents.Resources:Diabetes Connections Website: https://diabetes-connections.com/Stacey's Book: https://diabetes-connections.com/product/the-worlds-worst-diabetes-mom/Stacey on Twitter: https://twitter.com/staceysimmsStacey on Instagram: https://www.instagram.com/staceysimms/Jon Gay / JAG in Detroit Website: http://jagindetroit.com/JAG on Twitter: https://twitter.com/jagindetroitJAG on Instagram: https://www.instagram.com/jagindetroit/ 

Monologue Dr. Joel Wallach begins the show discussing common chronic disease states. Outlining obesity, diabetes, kidney failure, high blood pressure and cancer. Stating they are all preventable through proper diet and nutritional supplementation. Contending that most of these are also reverable through lifestyle changes and supplementation. Pearls of Wisdom Doug Winfrey and Dr. Wallach discuss a survey of diabetics. Finding that nearly half don't always take their medications because they can't afford them. Three companies Eli Lily, Sanofi and Novo Nordisk control 99% of the market. There also is no generic version of insulin even though the drug has been around for 100 years. From 2003 to 2013 the price of insulin has nearly tripled. Callers Joe has osteoporosis of the skull and trigeminal neuralgia. Thomas has incontinence and a leaky bladder. Patricia's mother is experiencing memory loss and has high blood pressure. Cooper's dog is having difficulty breathing through it's nose. Carlos's wife has a swollen left foot following long drive as a passenger in a car. Call Dr. Wallach's live radio program weekdays from noon until 1pm pacific time at 831-685-1080 or toll free at 888-379-2552.

In this episode, we talk to Rich Razgaitis (Co-Founder & CEO of FloWater) as we discuss how he started his company, what he looks for when turning around a company, and his passion to drastically reduce plastic water bottles.  **More On Rich** Rich “Raz” Razgaitis is the Co-Founder and Chief Executive Officer of FloWater, where he leads the Denver-based company in its vision to create a new distributed and decentralized water platform. The company is on a mission to disrupt the drinking water industry by delivering the best-tasting water in the world and eliminate single-use plastic water bottles and packaging waste. FloWater has become the beverage of choice for such companies as Google, Red Bull, prAna, Oneill, Play Station, Specialized Bikes, Alaska Airlines and Xponential Fitness, as well as the Oakland school system. Since the company launched in 2013, its proprietary, new-tech water Refill Stations have saved more than 130 million plastic bottles from the environment and is on track to save over one billion plastic single-use bottles by 2022. Razgaitis originated the concept and product development of FloWater and has scaled the brand significantly since its initial distribution in only one state: Today, FloWater Refill Stations are used daily at over 5,000 hotels, schools, corporations, gyms, retailers and events in nearly 50 states. Razgaitis' role is focused around financial and business strategy, investor relations, team hiring and organizational development, product development, and strategic growth partnerships, while overseeing operational execution—from manufacturing to customer service. He recently secured $15mm in Series B growth funding for FloWater. In 2019, FloWater was recognized as a “Top 500” company on the annual INC 5000 list of fastest-growing growing privately-held companies in America. In his career, Razgaitis has been passionate about building brands and teams. Since 2002, he has served in CEO/president-level roles in several venture capital-backed start-ups, privately held turnaround, and growth companies, and he brings insight from those experiences to his work today at FloWater. Razgaitis was the CEO of several consumer-tech companies, including DealOn, an e-commerce company that developed the Web's first deal-commerce exchange, and another, MyTownPerks, which built the first PCI-complaint, the cloud-based loyalty program for B2B. (Both companies were subsequently acquired.) Razgaitis has deep experience in the consumer-goods industry, having led personal-care and nutrition company Univera into fast growth, with revenues doubling from $35 million to $100 million per year. With a specialty in rebuilding brands, Razgaitis also restarted a privately held consumer company, Blaine Pharmaceuticals, where he led product development and licensing of a dozen new products and drove commercialization into over 30,000 food and drug stores nationwide. He started his career in Fortune 500 companies, including Johnson & Johnson and Eli Lily. Razgaitis grew up in the Midwest and holds a BA in marketing and an MBA in general business and marketing from Anderson University. When not working, you can find Razgaitis spending time with his two teenage daughters, where he gets to refine his ‘dad jokes,' or studying his Enneagram, volunteering with Defy Ventures, which focuses on ending mass incarceration and recidivism or riding a motorcycle in the summer and snowboard in the winter.   Follow Rich on LinkedIn Visit our website TheStartupLifePodcast.com Follow The Startup Life Podcast Facebook Page Want gear from The Startup Life? Check out our gear! Check out other great podcasts from The Binge Podcast Network.   Written by: Dominic Lawson Executive Producers: Dominic Lawson and Kenda Lawson Music Credits: **Show Theme**  Behind Closed Doors - Otis McDonald  **Break Theme** Cielo - Huma-Huma  Sponsors/Partners Go to Payoff.com/TheStartupLife to learn more. Go to the Phillip Stein and use code SLEEPEZ to get 10% of your new Philip Stein Sleep Bracelet.  Use code BETTEREVERYDAY for 30% everything sitewide at ladder.sport. That's “BETTEREVERYDAY” for 30% off at ladder.sport. Go to Save the Children dot org slash save kids orwww.savethechildern.org/savekids

Monologue Dr. Joel Wallach begins the show discussing common chronic disease states. Outlining obesity, diabetes, kidney failure, high blood pressure and cancer. Stating they are all preventable through proper diet and nutritional supplementation. Contending that most of these are also reverable through lifestyle changes and supplementation. Pearls of Wisdom Doug Winfrey and Dr. Wallach discuss a survey of diabetics. Finding that nearly half don't always take their medications because they can't afford them. Three companies Eli Lily, Sanofi and Novo Nordisk control 99% of the market. There also is no generic version of insulin even though the drug has been around for 100 years. From 2003 to 2013 the price of insulin has nearly tripled. Callers Joe has osteoporosis of the skull and trigeminal neuralgia. Thomas has incontinence and a leaky bladder. Patricia's mother is experiencing memory loss and has high blood pressure. Cooper's dog is having difficulty breathing through it's nose. Carlos's wife has a swollen left foot following long drive as a passenger in a car. Call Dr. Wallach's live radio program weekdays from noon until 1pm pacific time at 831-685-1080 or toll free at 888-379-2552.

Consider how a fraud audit using data analytics can help to detect or prevent bribery and corruption where the primary sales force used by a company are China based employees defrauding their company by using false expense reports to create a pot of money to use as a slush fund to pay bribes. Here you can think back to the Eli Lilly FCPA enforcement action up to the GSK problems as examples of where employees used their expense accounts not for personal use but for greater corporate malfeasance. This double dipping technique led to two anti-bribery compliance enforcement actions. One in the U.S. involving Eli Lily and a second in China involving the U.K. pharmaceutical entity GSK. The risk is real and by using ongoing data monitoring you might not only get ahead of the legal violation, but you would have a much more efficient business process going forward. Three key takeaways:  The typical fraud audit will get down into the weeds with data analytics. Split dollar expenses are key metric. Double-dipping can lead to larger problems.

Big pharmaceutical company Eli Lily was hiding the truth about the harms caused by their antipsychotic medication called Zyprexa -- until lawyer Jim Gottstein got a hold of the evidence and shared it with the New York Times.  You will not be surprised to hear that Eli Lily’s lawyers went after Jim hard with criminal charges to destroy his career, his livelihood and his freedom. In my interview with Jim about his personal experience with the mental health system, and his legal career focused on mental health, I ask him why he’s exposing big pharma deceit now in his new book The Zyprexa Papers.  Jim also tells about his personal experience with psychosis when he was over worked and under slept, and woke suddenly one night and thought he was being chased by the devil. Jim threw himself out a 2nd story window to escape. Fortunately, Jim is also skydiver, and knew how to roll his landing without injury. But it was Jim’s lived experience in the mental health system that prepared him for legal battles representing clients about mental health issues. Jim’s lived experience with the mental health system is priceless, adds value to a good legal defense, and cannot be taught in law school.  Jim also tells the story of how he became the lawyer to expose Eli Lily’s lies about the safety of their Zyprexa medication and the impact that had on his life and career. Jim became a leader in the psychiatric survivor community, founding patient organizations including PsychRights.org - and providing his legal services pro bono to clients who didn’t want to be forced to take medications. In The Zyprexa Papers, Jim gives a riveting first-hand account of what really happened, including new details about how a small group of psychiatric survivors spread the Zyprexa Papers on the Internet untraceably. All of this within a gripping, plain-language explanation of complex legal maneuvering and his battles on behalf of Bill Bigley, the psychiatric patient whose ordeal made possible the exposure of the Zyprexa Papers. The Zyprexa Papers included hundreds of internal Eli Lilly documents and emails that showed company officials knew their best-selling drug was severely harming people while scarcely helping anyone. Release of the papers exposed the abuses of the drug industry besides the harm that Zyprexa was doing. The series of front page stories in "The New York Times" could have saved tens of thousands of lives according to Jim's estimate. The public benefits greatly from Jim’s efforts, not only because of the life-saving information he released, but also because he’s a courageous model for other people to follow in exposing the predatory practices in the pharmaceutical industry. SHOW NOTES: 0:06:00 Jim was born in Anchorage Alaska in 1953 - it was a nice place to grow up - he was a pretty normal boy, he got to play little league, walk around town, ride bikes - when Jim was born Anchorage only had about 25,000 people, but now it is close to 400,000 0:07:00 Jim went to the University of Oregon to study business and to get a degree in finance, but one of the required courses was business law, and he didn't miss a question the entire term - he thought it may be a bette fit for him, so he took advanced business law and then decided to go to law school 0:08:00 Jim didn't do well enought in high school to get into any 'good' schools, and wanted to keep his options open by doing well in college - his 1st term was okay with a lot of Bs - Jim decided he had too much free time so increased his number of courses - the next term he got all As with one B 0:09:00 By over loading his courses, he graduated in 3 years - in his last term he needed 10 hours of anything to graduate, so he took 10 hours of teaching sky diving 0:10:00 Jim got his pilot's license when he was 17 - and then went to Harvard for law school 0:11:00 Jim's mom got him a job for lawyer Bob Goldberg, son of Justice Arthur Goldberg who was on the US Supreme Court - Bob had to move to Alaska to escape his father's shadow - Bob represented some of the Native groups 0:12:00 After a few years, Jim opened his own law practice and also decided to run for the State Senate, had traveled to Europe and Israel so was jet lagged and not getting enough sleep and Jim had a psychotic break - Jim had gone to his father's place to sleep but woke at 1am and thought the devil was coming for him - he was on the 2nd floor of the house and looked out the window 0:13:00 Jim thought he could jump far enough to miss the pavement and land on the grass - he jumped out the window and did a rolling landing parachute jump and ran across the street to the school parking lot but thought the devil was still chasing so kept looking over his shoulder - he was put in a straight jacket and hauled off to the Alasks Psychiatric Institute and they pumped him full of something that put him to sleep 0:14:00 Jim has always counted on his mind to accomplish what he set out to do and what was going on - so it was a shock that his mind could become completely unreliable - JIm remembers waking in the hospital and the male nurse asking Jim what day it was 0:15:00 Jim asked how long he'd been asleep - so the nurse noted that Jim wasn't oriented to time - so that was the start of the Alice in Wonderland experience of being in a psychiatric hospital - Jim was given Melaril , he told them he didn't want the psych med thorazine - thorazine was the first of the neuropleptic drugs for people with schizophrenia - it blocks about 80% of the dopamine, so they are basically chemical lobotomies 0:16:00 Jim knew he didn't want to have a 'committed involuntarily' label, so he signed himself in for treatment, but it was hardly voluntary - Jim's fiancee said he was still campaigning in the psych ward, handing out baseball caps, so Jim was pretty out of it - but was doing better and released after 30 days - Jim's not sure the medication did much for him 0:17:00 Jim's father connected Jim with a psychiatrist in New Rochelle, New York and he diagnosed Jim with biploar disorder - but the psych hospital had diagnosed him with atypical psychosis - Jim didn't find that psychiatrist very helpful - then Jim's mother connected him with another psychiatrist, Robert Alberts, who had been a Japanese prisoner of war - Jim says Robert was a wonderful person and told Jim that any one who misses enough sleep will become psychotic - and that Jim needed to manage that - Jim credits Robert with saving Jim from being made permanently mentally health by the mental health system because Jim had that he would never practice law again 0:18:00 When he told hospital staff he'd gone to Harvard law school, that confirmed to them Jim was delusional - Jim didn't accept their conclusion he'd never be able to practice law again, they'd call it 'denial' - Jim says 'denial' of being mental ill is one of the most positive things you can do - because the message of the mental health system is 'abandon all hope ye who enter here' 0:19:00 When in the hospital, they wanted to put Jim on lithium - he said he was a pilot and he couldn't fly if he was taking lithium, but they didn't care about that - so they creatine clearance test to his kidney function because lithium is hard on the liver and Jim's known a number of people killed by lithium - to do the test, they needed a kidnay biopsy, but the doctor couldn't find Jim's kidney's to do the test 0:20:00 Jim finds that work pressure with deadlines - and the habit is to always make the document better and file at the last minute - so Jim tries to file the day before so he doesn't have that sleep problem 0:21:00 Jim knows that if he's not getting enough sleep he can get into trouble, he knows the signs - the first sign is that Jim gets more witty with rejoinders, but nobogy notices except himself - then he'll have 'thought blocking' when he just stops for a few seconds when he's talking (his thoughts are blocked) - the next stage is that Jim thinks people are looking at him funny - he deals with that by telling himself that he's probably not acting funny 0:22:00 Then he'll also try to look at himself from 'above' to see if he's doing anything weird - at that point Jim may take a benzodiazipine (Halcyon) - just to break the cycle and get a nights sleep - it usually only takes 1 pill and then it'll be a year before he needs it again - benzos are highly addictive so its important not to take them daily 0:23:00 The FAA (Federal Aviation Administration) said Jim couldn't fly for 2 days after taking a benzo 0:24:00 Jim got involved in the legal side of mental health simultaneiously with his own psychotic break - in 1956 Congress enacted the Alaska Mental Health Enabling Act and gave a bunch of land for that purpose - later another Act redisgated that land for the state and said they'd maybe pay for it 0:25:00 Jim's mother was head of the Alaska Mental Health at the time and went to Congress and said you can't take this land, that's not legal - they said we don't care - so they sued them and won a billion dollar settlement 0:26:00 Jim found a couple of mental health 'consumer' groups - he was also on the Board of the Alaska Mental Health - then in 2002, Jim read Mad in America, Bad Science, Bad Medicine and the Enduring Mistreatment of the Mentally Ill by Robert Whittaker - to Jim it was a raodmap to challenging forced psychiatric drugging - JIm founded the Law Project for Psychiatric Rights (PsychRights.org) - and it challenged that and shock therapy 0:27:00 PsychRights also educates the public about these medications and shock therapy and their risks - Jim says we shouldn't call ECT (electro convulsive therapy) 'therapy' because it is not 0:28:00 The shock machines were invented in the 50s and have been modified since then - but before the FDA was responsible for regulating medical devices - but they didn't do that for 20 - 30 years - then in the last year they basically said that shock treatment is not harmful and we're not going to regulate them - Jim's says that is outrageous 0:29:00 Just shows how people in psychiatry just don't think - they're running electricity through the brain to cause a grand mal seizure, where neurologists do everything they can to prevent grand mal seizures - the convulsions were so intense people would break bones, bite through their tongue - now they anaesthetize them, but that requires more electricity to cause the convulsion 0:30:00 Dr Peter Breggin has written great psychiatry books - and he says electro shock is really a closed head injury - some people when they get a head injury, become euphoric for a while - but people have horrendous memory loss they don't get back - Jim thinks electro shock should be banned - its barbaric 0:31:00 A court in Conneticut has ordered a woman to be shocked against her will 500 times - that's the thing about psychiatry, 'if something doesn't work, do more of it' - 0:32:00 In November 2006 Jim received a call an expert witness in a massive lawsuit over side effects from the psych med Zyprexa - like diabetes and other metabolic problmes Eli Lily had not owned up to - he said he had documents showing Eli Lily knew from the beginning, hid it from the doctors and they were illegally marketing it to children and the elderly - but he was under a secrecy order - however if he was subpoanaed in another case - he wanted to know if Jim would do that - there's more to the story and that's what is book The Zyprexa Papers is about the New York Times published some articles 0:33:00 The expert witness had also been working with a writer from the New York Times, Alex Berenson - the expert witness gave the documents to Jim - there were a series of front page stories in the NYT and then Eli Lily came after Jim with criminal charges and to the Alaska Bar Association to try to get Jim disbarred 0:34:00 Zyprexa is a 2nd generation neuroleptic medication, also called antipsychotic, but that's just a marketing term - 'neuroleptic' means 'seize the brain' and that is what they do - in the 90s they started atypical neuroleptics which supposedly didn't have negative effects like tardive dyskinesia (results in involuntary, repetitive body movements, which may include grimacing, sticking out the tongue, or smacking the lips) - basically drug induced Parkinson's Disease 0:35:00 It blocks 70 - 90% of dopamine in the basal ganglia, same thing with Parkinson's patients - licking their lips, strange movements - and doctors interpret that in Zyprexa patients as mental illness, not as negative effects of Zyprexa - Eli Lily said this new generation of atypical meds didn't have tardive dyskenesia and that was a lie - another negative effect was neuroliptic malignant syndrome and it is often fatal, and Eli Lily lied about that too 0:36:00 Risperdal causes little boys to grow breasts, called gynecomastia - Seroquel causes problems, like elongates the heart rhythm and that can cause death - they are putting Veterans on Seroquel and another medication and they are dying in their sleep from this drug cocktail - they were prescribed originally for schizophrenia and the manic phase of bipolar disorder - cut in the US a doctor can prescribe any drug for any thing 0:37:00 Pharmaceuticals can only market a drug for a specific illness, but they do it anyway through various guises and artifices, like ghost writing articles, basically huge fraud perpetrated on the public - Dr David Eagleman was the expert witness and had these documents proving Eli Lily's lies and thought the public should know, but he was under a secrecy order 0:38:00 Dr Eagleman was looking for someone to subpeona him and Jim had just won a case for Faith Myers where they wanted to force her to take Zyprexa - Jim had a great witness, Dr Grace Jackson, and she analyzed the papers on which Zyprexa was given approval by the FDA, and she could see it caused diabetes just from that - but not just diabetes 0:39:00 People would gain a 100 pounds in a year - Dr Jackson found the studies were fraudulent - because the meds block dopamine, the first thing the brain does is try to pump out more dopamine - then after a few weeks it grows more dopamine receptors 0:40:00 So abrupt withdrawal causes some people to experience psychosis - but the doctor will say 'see what happens when you're not on medication' - but some people did quite well with the sudden withdrawal, but those people were thrown out of the study 0:41:00 About 2/3 of people in the study dropped out because of the negative effects - so Dr Jackson put all this in a report 0:42:00 Jim shared the documents with the NYT in 2006 and found someone to put them on the internet 0:43:00 Then a group called Psychiatric Survivors got involved - another group Mind Freedom.org with David Oakes, and they also helped get it out - Jim says it was amazing how Eli Lily could whip up Federal Judges to issues orders against Jim without him even being given notice 0:44:00 Psychiatric survivor Eric Weiland had posted them on his website and Eli Lily harassed and threatened him so he took them down - Pat Riser passed away a few years ago probably a result of psych drugging, he wrote the Eli Lilly and said 'geez, I saw these in the NYT and downloaded them and made a few CDs of them and sent them to newspapers and family and friends and went to... 0:45:00 ...handed them out in a shopping plaza parking lot - I didn't know they were illegal and sorry, I'm not going to be able to get them all back' - that's one of Jim's favorite vignettes - but Eli Lily had endless money to fight Jim 0:46:00 Jim testified and the judge ruled Jim conspired to steal the documents and a 'criminal act' and that set up Jim for criminal contempt charges 0:47:00 One of the clients in the case had a Gaurdian, and it was only the Gaurdian who could sign release papers so Jim could look at the client's medical records 0:48:00 Jim did get the medical records and the client had been drugged with Zyuprexa against his will - he was held down and injected with it 0:49:00 Eli Lily had portrayed themselves as the 'victim' in the lawsuit, so going after Jim, and the ensuing publicity, would've make Eli Lily look bad - they could have crushed Jim financially - so it was scary because the consequences could have been severe, including jail time 0:50:00 Zyprexa is still available and still forced - about 3 years ago Jim had financial troubles and had to give up most of the pro bono Pysch Rights work he'd been doing for 14 years and boost his law practice 0:51:00 After a year he had some clients but not a lot, so used his time to write the book - Jim would like the public to be aware because he thinks they'll be shocked by Jim's representation of Bill Bickley and to stop him from being drugged against his will 0:52:00 Jim represented him for 4 years, 10 trials and 5 trips to the Alaska Supreme Court - one of those decisions was an important precedent 0:53:00 Jim's says people are really taken with the 2 chapters on his defence of Bill Bickley and how the system is set up against patients, it is basically a kangaroo court - Bill's wife had divorced him and took custody of the 2 kids and sued him for child support which he couldn't afford - he had a good job as a heavy equipment operator and had a nervous breakdown - so Jim tries to convey how people's lives are ruined by what psychiatry does to them 0:54:00 In 2007, Dr Jackson testified that if Bill was continued to be drugged, he'd be dead within 5 years, and she was off by 6 months - Bill's Gaurdian didn't want Jim representing Bill, because they wanted him drugged - Jim won about half the cases for Bill - the Gaurdian told Jim that Bill didn't want Jim to represent him anymore, and Jim said that he'd never heard Bill say that 0:55:00 The judge asked Bill if he wanted Jim to represent him, and Bill said 'Jim knows a lot about me. And I'm the president." - the Gaurdian changed their tune after that, and said that Bill was not competent to make the decision - while Jim won half of Bill'ls cases, the Public Defendor who lost all but one of the cases - but the Alaska Supreme Court decided that Bill could not choose Jim as his lawyer, and that is a very frightening thing - so they got to drug him without constraint and he died within a couple of years 0:56:00 Jim pointed out to the Gaurdian that these drugs shorten lives, and the Gaurdian argued that quality of life is important - but they didn't care what Bill thought of his quality of life, and it was better without the drugs 0:57:00 One of the reasons Jim wrote the Zyprexa Papers is to bring people's attention - it is available on Amazon in Kindle or paperback 0:58:00 To connect with Jim, go to PsychRights.org and email him through that site 0:59:00 Jim talks to people all the time who had no idea this was going on - 'you can learn from your mistakes, but its better to learn from other people's mistakes' - hopefully he can prevent other people from having this sort of terrible thing happen to them   Twitter: https://twitter.com/jimgottstein   Connect with Jim Gottstein on Facebook: https://www.facebook.com/jim.gottstein   http://psychrights.org/http://gottsteinlaw.com/Author of The Zyprexa Papershttps://www.amazon.com/dp/B0838YYYWV   Be a podcast patron Support Medical Error Interviews on Patreon by becoming a Patron for $2 / month for audio versions.  Premium Patrons get access to video versions of podcasts for $5 / month.   Be my Guest I am always looking for guests to share their medical error experiences so we help bring awareness and make patients safer. If you are a survivor, a victim’s surviving family member, a health care worker, advocate, researcher or policy maker and you would like to share your experiences, please send me an email with a brief description:  RemediesPodcast@gmail.com    Need a Counsellor? Like me, many of my clients at Remedies Counseling have experienced the often devastating effects of medical error. If you need a counsellor for your experience with medical error, or living with a chronic illness(es), I offer online video counseling appointments. **For my health and life balance, I limit my number of counseling clients.**  Email me to learn more or book an appointment:  RemediesOnlineCounseling@gmail.com   Scott Simpson:  Counsellor + Patient Advocate + (former) Triathlete I am a counsellor, patient advocate, and - before I became sick and disabled - a passionate triathlete. Work hard. Train hard. Rest hard. I have been living with HIV since 1998. I was the first person living with HIV to compete at the triathlon world championships. Thanks to research and access to medications, HIV is not a problem in my life. I have been living with ME (myalgic encephalomyelitis) since 2012, and thanks in part to medical error, it is a big problem in my life.   Counseling / Research I first became aware of the ubiquitousness of medical error during a decade of community based research working with the HIV Prevention Lab at Ryerson University, where I co-authored two research papers on a counseling intervention for people living with HIV, here and here.  Patient participants would often report varying degrees of medical neglect, error and harms as part of their counseling sessions.   Patient Advocacy I am co-founder of the ME patient advocacy non-profit Millions Missing Canada, and on the Executive Committee of the Interdisciplinary Canadian Collaborative Myalgic Encephalomyelitis Research Network. I am also a patient advisor for Health Quality Ontario’s Patient and Family Advisory Council, and member of Patients for Patient Safety Canada. Medical Error Interviews podcast and vidcast emerged to give voice to victims, witnesses and participants in this hidden epidemic so we can create change toward a safer health care system.   My golden retriever Gladys is a constant source of love and joy. I hope to be well enough again one day to race triathlons again. Or even shovel the snow off the sidewalk.

Monologue Dr. Joel Wallach begins the show discussing common chronic disease states. Outlining obesity, diabetes, kidney failure, high blood pressure and cancer. Stating they are all preventable through proper diet and nutritional supplementation. Contending that most of these are also reverable through lifestyle changes and supplementation. Pearls of Wisdom Doug Winfrey and Dr. Wallach discuss a survey of diabetics. Finding that nearly half don't always take their medications because they can't afford them. Three companies Eli Lily, Sanofi and Novo Nordisk control 99% of the market. There also is no generic version of insulin even though the drug has been around for 100 years. From 2003 to 2013 the price of insulin has nearly tripled. Callers Joe has osteoporosis of the skull and trigeminal neuralgia. Thomas has incontinence and a leaky bladder. Patricia's mother is experiencing memory loss and has high blood pressure. Cooper's dog is having difficulty breathing through it's nose. Carlos's wife has a swollen left foot following long drive as a passenger in a car. Call Dr. Wallach's live radio program weekdays from noon until 1pm pacific time at 831-685-1080 or toll free at 888-379-2552.

Monologue Dr. Joel Wallach begins the show discussing common chronic disease states. Outlining obesity, diabetes, kidney failure, high blood pressure and cancer. Stating they are all preventable through proper diet and nutritional supplementation. Contending that most of these are also reverable through lifestyle changes and supplementation. Pearls of Wisdom Doug Winfrey and Dr. Wallach discuss a survey of diabetics. Finding that nearly half don't always take their medications because they can't afford them. Three companies Eli Lily, Sanofi and Novo Nordisk control 99% of the market. There also is no generic version of insulin even though the drug has been around for 100 years. From 2003 to 2013 the price of insulin has nearly tripled. Callers Joe has osteoporosis of the skull and trigeminal neuralgia. Thomas has incontinence and a leaky bladder. Patricia's mother is experiencing memory loss and has high blood pressure. Cooper's dog is having difficulty breathing through it's nose. Carlos's wife has a swollen left foot following long drive as a passenger in a car. Call Dr. Wallach's live radio program weekdays from noon until 1pm pacific time at 831-685-1080 or toll free at 888-379-2552.

Co-hosts Kristyn and Karin share KonMari inspired storage solutions and tools you can use to uplevel your space and honor the things you love. We chat about how to store and organize after you’ve completed your KonMari Tidying Journey one signature clutter category at a time. We want to hear from you! Tell us your burning tidying questions or share stories about how KonMari has impacted your life. Find us at www.sparkjoypodcast.com and click “Ask Spark Joy” to leave a question or comment for a chance to be featured on next week’s show. While you’re there, sign-up to join our Spark Joy podcast community and get notified when each episode airs. You can also join the Spark Joy podcast community on Facebook, Instagram or Twitter at the handle @sparkjoypodcast. In this episode, you’ll enjoy: Joy Checks -Karin is speaking at the invitation of Eli Lily and Co. during the ASCO International Conference -Kristyn has committed to writing 30 blog posts in 30 days as one of her Tidy Mastermind goals. Connect via fortheloveoftidy.com to follow her progress -Review the importance of tidying by category instead of location in Spark Joy Ep 9 | Tidying by Location is a Fatal Mistake KonMari Storage Tips -Organize items that spark joy so they are visible within a designated space -Things are stored so that they are easy to put away and easy to get out -Storage should bring you a sense of order and calm -Reuse and repurpose wherever possible. Shop your home -Save your bins and baskets until you’ve joy checked the very last item -Storage is fluid -Reduce visual clutter KonMari Tidy Tools -Your calendar -The Tidy Home Joy Journal - Join The Spark Joy Club to receive your copy and exclusive access to the SJC community -Your Vision (see Spark Joy Ep 5 | How to Visualize Your Ideal Lifestyle and Living Environment -Trash bags: Glad Large Drawstring Recycling Bags -The Spark Joy podcast! Listen while you tidy! -Label Remover -Tape measure Clothing Category Storage -Principles of KonMari clothes hanging: -Rise to the right -Lighter, shorter, more delicate things on the right -Heavy, longer, darker things toward the left -Always, like things go together -Hanger options: -Velvet Hangers -Wooden hangers -Bins for clothing storage: -Bins for open shelving to create drawers -Underbed Storage Note: Following Feng Shui principles can be done if you are so inclined, so be sure to review our episode Ep 71 | Feng Shui with Master Laura Cerrano -Future donation bag/box -Three closet essentials: -Hamper -Step Stool -Trash Can -Drawers for clothing storage: -Soft Sided Boxes -Drawer Dividers Books Category Storage -For a review of how to sort books head over to Spark Joy Ep 75 | Exploring the KonMari Book Controversy with Robin Mitchell -Book Ends** Paper Category Storage -For a review of the three types of KonMari paper categories, go to Spark Joy Ep 45 | KonMari Paper Category: Cutting Paper Clutter -Tools for paper storage: -Locking File Box -Fun File Folders -Label Maker -Slice Precision Cutter -Fireproof Box -Virtual paper storage -Dropbox -GoogleDocs -Evernote Komono Category Storage -Spark Joy listener Angela submitted a question about managing charging stations and office items: “I’m starting this journey but the area that bothers me the most is how to organize an office/charging area. These both tend to lend way to the kitchen for ease of use and accessibility. We are a family of five so we have a lot of devices. How would you suggest maintaining an area in the kitchen that could mainstream both of these purposes (paperwork and device charge/overnight storage) without cluttering the counters?” -Cord solutions: -Kitchen: Mesh Stackable Shelves -Kitchen: Shelf Liners -Kitchen: SCUBB Ikea Boxes -Toiletries: Kristyn's favorite Soap Dispenser and Soap Refill -Make up: Acrylic Makeup Organizer -Holiday decor: wrapping paper holder and ornament holder Sentimental Category Storage -The importance of making your sentimental storage thoughtful, meaningful and safe -Milestone Binder - Full "how to" video available with Spark Joy Club membership -Review methods for digitizing your sentimental items in Spark Joy Ep 55 | Digitizing Sentimental Items Gems: -"We want you be more mindful of the things you’re keeping before jumping into finding the perfect place for your things to be stored. Stuff over storage." -"Storage should bring you a sense of order and calm, whatever that means for you." -"Their real joy is based on being able to see them and to acknowledge what they represent to us." -"Is this a chance to highlight your legacy, who would be happier if I keep this?' -"In some ways, the organizing step is really the most fun and it serves as your reward for all of the hard work joy checking and editing that will takes place in your home." You can find Karin Socci at The Serene Home You can find Kristyn Ivey at For the Love of Tidy

Fortune Magazine CEO Alan Murray joins Tim to tell the story behind the Fortune 500, its history, its significance today, and what it has said over the years about America's and the world's business evolution. https://traffic.libsyn.com/shapingopinion/Fortune_500_auphonic.mp3 Fortune Magazine was founded in 1929 by Henry Robinson Luce. If that date doesn't mean anything to you at first glance, keep in mind the stock market crash that led to the Great Depression happened on October 24, 1929. This was seven years after he had cofounded Time magazine with two Yale classmates. When Henry founded Fortune magazine, he said it should be for “wealthy and influential people,” and it should be “surpassingly beautiful” so that when readers turn the pages, they will pay more, and they did. In its first year, subscribers paid $10 per year for the magazine, an unheard of price at that time. In the process, Fortune Magazine featured the work of some of the country's greatest thinkers and writers, from Ernest Hemingway and Archibald MacLeish to John Kenneth Galbraith. The first Fortune 500 list was published in 1955. Edgar P. Smith was an assistant managing editor at the magazine. He's the one who came up with the idea for the now iconic list. In that fist year, the Fortune 500 rankings listed only companies that were in the manufacturing, mining and energy sectors. This made the list exclusive to several already well-known companies. General Motors was the top company on the list. Its annual revenues then were $9.8 billion. The Fortune 500  Yearly list of 500 of the largest U.S. Companies ranked by total revenues for the respective fiscal year. This list is compiled using the most recent figures for revenue and includes both private and public companies. Private companies must have publicly available revenue data. It excludes private companies that do not file financial statements with government agencies, foreign corporations, U.S. companies that have been consolidated by other companies, and companies that do not report full financial statements for at least three quarters of the current fiscal year. The History of the Fortune 500 52 of the original Fortune 500 are still on the list. These include: 3M, DowDupont, Merck, Abbott Laboratories, Eli Lily, Motorola, ExxonMobil, General Dynamics, General Electric, General Mills, General Motors, Goodyear, Hershey, IBM, Kellogg, Kraft-Heinz, Lockheed Martin, Cummins, Colgate-Palmolive, Coca-Cola, PepsiCo, Chevron, Caterpillar, Campbell Soup, Boeing, Whirlpool,, Rockwell Automation, Procter & Gamble, and PPG Industries. Over the years, more than 1,800 American companies have been featured on the Fortune 500.  Changes have occurred – mergers, acquisitions, bankruptcies, changes in society, recession have all contributed to the changing list. The Fortune 500 is more than a ranking, it is a reflection of the performance and evolution of America's private sector. The biggest change to the list happened in 1994. That was when it added service companies for the first time. That year, service companies made up 291 of the 500 entries. What the Fortune 500 Says About Society Long Gone - 1955 – American Motors, Brown Shoe, Studebaker, Collins Radio, Detroit Steel, Zenith Electronics, National Sugar Refining. Still Here – Every year since 1955 – Boeing, IBM, Procter and Gamble, Whirlpool. In 2019 but not 1955 – Amazon, Facebook, eBay, Home Depot, Microsoft, Google, Netflix, Target. This year's top ten: Walmart Exxon Mobile Apple Berkshire Hathaway Amazon United Health Group McKesson CVS Health AT&T Amerisource Bergen Links The Fortune 500 Who Says Elephants Can't Dance?, by Louis Gerstner, Amazon Fact Sheet: What is the Fortune 500 List? , Investopedia About this Episode's Guest Alan Murray Alan Murray is President and CEO of Fortune. During his tenure as Editor-in-Chief,

Fortune Magazine CEO Alan Murray joins Tim to tell the story behind the Fortune 500, its history, its significance today, and what it has said over the years about America’s and the world’s business evolution. https://traffic.libsyn.com/shapingopinion/Fortune_500_auphonic.mp3 Fortune Magazine was founded in 1929 by Henry Robinson Luce. If that date doesn’t mean anything to you at first glance, keep in mind the stock market crash that led to the Great Depression happened on October 24, 1929. This was seven years after he had cofounded Time magazine with two Yale classmates. When Henry founded Fortune magazine, he said it should be for “wealthy and influential people,” and it should be “surpassingly beautiful” so that when readers turn the pages, they will pay more, and they did. In its first year, subscribers paid $10 per year for the magazine, an unheard of price at that time. In the process, Fortune Magazine featured the work of some of the country’s greatest thinkers and writers, from Ernest Hemingway and Archibald MacLeish to John Kenneth Galbraith. The first Fortune 500 list was published in 1955. Edgar P. Smith was an assistant managing editor at the magazine. He’s the one who came up with the idea for the now iconic list. In that fist year, the Fortune 500 rankings listed only companies that were in the manufacturing, mining and energy sectors. This made the list exclusive to several already well-known companies. General Motors was the top company on the list. Its annual revenues then were $9.8 billion. The Fortune 500  Yearly list of 500 of the largest U.S. Companies ranked by total revenues for the respective fiscal year. This list is compiled using the most recent figures for revenue and includes both private and public companies. Private companies must have publicly available revenue data. It excludes private companies that do not file financial statements with government agencies, foreign corporations, U.S. companies that have been consolidated by other companies, and companies that do not report full financial statements for at least three quarters of the current fiscal year. The History of the Fortune 500 52 of the original Fortune 500 are still on the list. These include: 3M, DowDupont, Merck, Abbott Laboratories, Eli Lily, Motorola, ExxonMobil, General Dynamics, General Electric, General Mills, General Motors, Goodyear, Hershey, IBM, Kellogg, Kraft-Heinz, Lockheed Martin, Cummins, Colgate-Palmolive, Coca-Cola, PepsiCo, Chevron, Caterpillar, Campbell Soup, Boeing, Whirlpool,, Rockwell Automation, Procter & Gamble, and PPG Industries. Over the years, more than 1,800 American companies have been featured on the Fortune 500.  Changes have occurred – mergers, acquisitions, bankruptcies, changes in society, recession have all contributed to the changing list. The Fortune 500 is more than a ranking, it is a reflection of the performance and evolution of America’s private sector. The biggest change to the list happened in 1994. That was when it added service companies for the first time. That year, service companies made up 291 of the 500 entries. What the Fortune 500 Says About Society Long Gone - 1955 – American Motors, Brown Shoe, Studebaker, Collins Radio, Detroit Steel, Zenith Electronics, National Sugar Refining. Still Here – Every year since 1955 – Boeing, IBM, Procter and Gamble, Whirlpool. In 2019 but not 1955 – Amazon, Facebook, eBay, Home Depot, Microsoft, Google, Netflix, Target. This year’s top ten: Walmart Exxon Mobile Apple Berkshire Hathaway Amazon United Health Group McKesson CVS Health AT&T Amerisource Bergen Links The Fortune 500 Who Says Elephants Can’t Dance?, by Louis Gerstner, Amazon Fact Sheet: What is the Fortune 500 List? , Investopedia About this Episode's Guest Alan Murray Alan Murray is President and CEO of Fortune. During his tenure as Editor-in-Chief,

Melissa Peoples is a Certified Microsoft Trainer with over 25 years of experience supporting C-Suite level executives in companies such as National Instruments, Dell, General Motors, The Ohio State University, AllState, and Eli Lily.We chat about managing board meetings, being vulnerable, and dealing with online trolls.Show notes at leaderassistant.com/13Subscribe at podcast.leaderassistant.comJoin the community at slack.leaderassistant.com or facebook.leaderassistant.com

Co-hosts Kristyn and Karin share KonMari inspired storage solutions and tools you can use to uplevel your space and honor the things you love. We chat about how to store and organize after you’ve completed your KonMari Tidying Journey one signature clutter category at a time. We want to hear from you! Tell us your burning tidying questions or share stories about how KonMari has impacted your life. Find us at www.sparkjoypodcast.com and click “Ask Spark Joy” to leave a question or comment for a chance to be featured on next week’s show. While you’re there, sign-up to join our Spark Joy podcast community and get notified when each episode airs. You can also join the Spark Joy podcast community on Facebook, Instagram or Twitter at the handle @sparkjoypodcast. In this episode, you’ll enjoy: Joy Checks -Karin is speaking at the invitation of Eli Lily and Co. during the ASCO International Conference -Kristyn has committed to writing 30 blog posts in 30 days as one of her Tidy Mastermind goals. Connect via fortheloveoftidy.com to follow her progress -Review the importance of tidying by category instead of location in Spark Joy Ep 9 | Tidying by Location is a Fatal Mistake KonMari Storage Tips -Organize items that spark joy so they are visible within a designated space -Things are stored so that they are easy to put away and easy to get out -Storage should bring you a sense of order and calm -Reuse and repurpose wherever possible. Shop your home -Save your bins and baskets until you’ve joy checked the very last item -Storage is fluid -Reduce visual clutter KonMari Tidy Tools -Your calendar -The Tidy Home Joy Journal - Join The Spark Joy Club to receive your copy and exclusive access to the SJC community -Your Vision (see Spark Joy Ep 5 | How to Visualize Your Ideal Lifestyle and Living Environment -Trash bags: Glad Large Drawstring Recycling Bags -The Spark Joy podcast! Listen while you tidy! -Label Remover -Tape measure Clothing Category Storage -Principles of KonMari clothes hanging: -Rise to the right -Lighter, shorter, more delicate things on the right -Heavy, longer, darker things toward the left -Always, like things go together -Hanger options: -Velvet Hangers -Wooden hangers -Bins for clothing storage: -Bins for open shelving to create drawers -Underbed Storage Note: Following Feng Shui principles can be done if you are so inclined, so be sure to review our episode Ep 71 | Feng Shui with Master Laura Cerrano -Future donation bag/box -Three closet essentials: -Hamper -Step Stool -Trash Can -Drawers for clothing storage: -Soft Sided Boxes -Drawer Dividers Books Category Storage -For a review of how to sort books head over to Spark Joy Ep 75 | Exploring the KonMari Book Controversy with Robin Mitchell -Book Ends** Paper Category Storage -For a review of the three types of KonMari paper categories, go to Spark Joy Ep 45 | KonMari Paper Category: Cutting Paper Clutter -Tools for paper storage: -Locking File Box -Fun File Folders -Label Maker -Slice Precision Cutter -Fireproof Box -Virtual paper storage -Dropbox -GoogleDocs -Evernote Komono Category Storage -Spark Joy listener Angela submitted a question about managing charging stations and office items: “I’m starting this journey but the area that bothers me the most is how to organize an office/charging area. These both tend to lend way to the kitchen for ease of use and accessibility. We are a family of five so we have a lot of devices. How would you suggest maintaining an area in the kitchen that could mainstream both of these purposes (paperwork and device charge/overnight storage) without cluttering the counters?” -Cord solutions: -Kitchen: Mesh Stackable Shelves -Kitchen: Shelf Liners -Kitchen: SCUBB Ikea Boxes -Toiletries: Kristyn's favorite Soap Dispenser and Soap Refill -Make up: Acrylic Makeup Organizer -Holiday decor: wrapping paper holder and ornament holder Sentimental Category Storage -The importance of making your sentimental storage thoughtful, meaningful and safe -Milestone Binder - Full "how to" video available with Spark Joy Club membership -Review methods for digitizing your sentimental items in Spark Joy Ep 55 | Digitizing Sentimental Items Gems: -"We want you be more mindful of the things you’re keeping before jumping into finding the perfect place for your things to be stored. Stuff over storage." -"Storage should bring you a sense of order and calm, whatever that means for you." -"Their real joy is based on being able to see them and to acknowledge what they represent to us." -"Is this a chance to highlight your legacy, who would be happier if I keep this?' -"In some ways, the organizing step is really the most fun and it serves as your reward for all of the hard work joy checking and editing that will takes place in your home." You can find Karin Socci at The Serene Home You can find Kristyn Ivey at For the Love of Tidy

In this episode of Occupation Station, we meet ACPHS grad Brian Carroll, who had an extremely satisfying career for decades with Eli Lilly and Company before recently retiring. Carroll talks about how his pharmacy background gave him greater credibility in working with physicians as a medical liaison. He recalls what a typical day on the job entailed and how communication skills he honed at ACPHS were called upon to help physicians in their roles of helping patients. Carroll also talks about why pharmacy students were sought after when he was being hired at Eli Lilly and what pharmaceutical companies are now looking for now when they make hiring decisions.

Your host Dr. Ed Gonzalez interviews Mr. Chuck Blakeman. He is a best-selling author and world-renowned business advisor and TED speaker. He has advised companies the likes of, Microsoft, Apple, Eli Lily, Sun Microsystems and many more Fortune 500 companies. He now uses his talents to advise Dentist with their businesses. You will find this discussion transformative.

Everywhere we look fiat currencies are burning down. What is the market telling us? Is something big about to happen. Every time the US Dollar goes higher, it's bad news for some country. While it might be affecting gold and cryptos negatively, the trend won't continue indefinitely. As we have seen over and over again, not only does the tree not grow to the sky, but markets have a nasty way of punishing investors who refuse to accept this immutable fact. As Ned predicted last month on this show, the Chinese have an insatiable appetite for soybeans. And while they were only too happy to levy reciprocal tariffs on US soybean products, it seems to have blown up in their faces. Unless they want to reduce beef and pork production, there's only one place to go, the good old USofA. Could Trump have known this already. More fun to follow. Ned has some great ag picks in addition to perennial favorite Archer Daniels Midland. Eli Lily is about to spin off their ag biz and it promises to be a major home run for those savvy enough to recognize it as such. And Ned doesn't believe all those nasty things they've been saying about Roundup!

Everywhere we look fiat currencies are burning down. What is the market telling us? Is something big about to happen. Every time the US Dollar goes higher, it's bad news for some country. While it might be affecting gold and cryptos negatively, the trend won't continue indefinitely. As we have seen over and over again, not only does the tree not grow to the sky, but markets have a nasty way of punishing investors who refuse to accept this immutable fact.  As Ned predicted last month on this show, the Chinese have an insatiable appetite for soybeans. And while they were only too happy to levy reciprocal tariffs on US soybean products, it seems to have blown up in their faces. Unless they want to reduce beef and pork production, there's only one place to go, the good old USofA. Could Trump have known this already. More fun to follow.  Ned has some great ag picks in addition to perennial favorite Archer Daniels Midland. Eli Lily is about to spin off their ag biz and it promises to be a major home run for those savvy enough to recognize it as such. And Ned doesn't believe all those nasty things they've been saying about Roundup!

Everywhere we look fiat currencies are burning down. What is the market telling us? Is something big about to happen. Every time the US Dollar goes higher, it's bad news for some country. While it might be affecting gold and cryptos negatively, the trend won't continue indefinitely. As we have seen over and over again, not only does the tree not grow to the sky, but markets have a nasty way of punishing investors who refuse to accept this immutable fact. As Ned predicted last month on this show, the Chinese have an insatiable appetite for soybeans. And while they were only too happy to levy reciprocal tariffs on US soybean products, it seems to have blown up in their faces. Unless they want to reduce beef and pork production, there's only one place to go, the good old USofA. Could Trump have known this already. More fun to follow. Ned has some great ag picks in addition to perennial favorite Archer Daniels Midland. Eli Lily is about to spin off their ag biz and it promises to be a major home run for those savvy enough to recognize it as such. And Ned doesn't believe all those nasty things they've been saying about Roundup!

Everywhere we look fiat currencies are burning down. What is the market telling us? Is something big about to happen. Every time the US Dollar goes higher, it's bad news for some country. While it might be affecting gold and cryptos negatively, the trend won't continue indefinitely. As we have seen over and over again, not only does the tree not grow to the sky, but markets have a nasty way of punishing investors who refuse to accept this immutable fact.  As Ned predicted last month on this show, the Chinese have an insatiable appetite for soybeans. And while they were only too happy to levy reciprocal tariffs on US soybean products, it seems to have blown up in their faces. Unless they want to reduce beef and pork production, there's only one place to go, the good old USofA. Could Trump have known this already. More fun to follow.  Ned has some great ag picks in addition to perennial favorite Archer Daniels Midland. Eli Lily is about to spin off their ag biz and it promises to be a major home run for those savvy enough to recognize it as such. And Ned doesn't believe all those nasty things they've been saying about Roundup!

Our special guest is Bill DeWees. author of the book How to Start and Build a 6 Figure Voice Over Business: Set Your VO Career On Fire. Bill has recorded thousands of radio & television commercials, narrations, learning/training programs, & audiobooks for a global audience. Believable is the first word that comes to most client’s minds when describing Bill’s voice. Trustworthy, Sincere, Authoritative, Friendly, Fresh, Powerful, Energetic, and Relatable are also accurate adjectives. Bill DeWees has been in the voice over business for more than 30 years, having recorded thousands of commercials, industrials, narrations, training videos, Internet videos, TV projects, educational scripts, IVR promotions, and other projects. As a voice professional, he wants his clients to think of him as the partner down the hall, that will deliver your voice over the way you want it, because to him, it’s about exceeding your expectations. If you are looking for a relatable, friendly voice for your next campaign, click the link in Contact information above, explore his profile and you too can have the “voice of the world” for your next campaign. For booking information, email Bill at: Booking@BillDeWees.com , call 815-520-3699 or check out BillDeWees.com. More helpful links to learn about voice overs: www.voice-over-training.org, Visit Youtube: www.youtube.com/user/VoiceOverExpert, http://www.voiceoverrevolutionevent.com/ Someone once described Bill as ‘the voice of the world.’ While John Cusack was the voice of the Chevrolet brand in America, he was the voice of Chevrolet’s Find New Roads world campaign. Bill has done voice work for some of the largest and best-known brands in the world. From Disney, Coca-Cola, Google, Microsoft and Warner Brother studios, to many of the Fortune 500's, he is the voice behind the product. Want to hear him in action, check out his Contact Info, there’s a YouTube link. goo.gl/oypthw. From commercials to narration, to explainer and training videos, one of his biggest niche markets is technical voice work. Bill makes the intimidating sound not so intimidating and the technical sound not so technical. His ability to create a trustworthy sound isn’t by accident. Bill has been a college professor, a business consultant, and a business coach. He's also worked for an Instructional Design firm creating training for Fortune 500 clients. Bill's voice over and voice credits include working for the following companies: Disney, Coca-Cola, Google, Microsoft, American Express, DreamWorks, Pizza Hut, Sears, Whirlpool, NBC Universal, Warner Brothers, National Geographic, Pepsi, Frito Lay, Shell, Pitney Bowes, Tiffany & Co., PGA Tour, Adidas, TD Ameritrade, Safeco, Dell, Lowe's, Exxon Mobil, Motorola, Toro, Oracle, Land O’ Lakes, Butterball, Best Buy, LG, Hitachi, Carlson Hotels, Morgan Stanley, Avaya, Time Warner, Makita, Carnival Cruise Lines, Dagedar Racers, Purina, UBS Financial, Rosetta Stone, Dannon, Volkswagen, Arm & Hammer, Syngenta, Bayer, Elanco, QVC, Boys & Girls Clubs of America, Pep Boys, Liberty Mutual, Unilever, Ramada, Nikon, Wells Fargo, Lenovo, Husqvarna, Bosch, Scripps Health, Professional Bullriders Association, HP, Prudential, CSG International, FILA, Hospira, Phillips, Cheesecake Factory, Sony, Eli Lily, FEMA, Walmart, Aramark, AAA, Symantec, McCulloch, Holcim, VMWaren, Accenture, Simon & Schuster, Nokia, BIC, Wahl, SPX, Lawyers.com, Monster.com, Enterprise, U.S. Dept of Education, IBM, Amgen, Tyco, Billy Graham Association, Intuit, Big Lots, SAP, PBS, CDM, Smith Underwriter’s Laboratory, Renault, Perry Ellis, PwC, Circle K, Strayer University, Dominos Pizza, CSX, Highlights for Children, ADT, and Ericsson. This is by no means a complete list.

This is an impactful hour for any startup that needs to grow a company from idea to profitability without debt and WITHOUT VENTURE CAPITAL! Melissa Burstein is a sales/marketing genius of a medical device company, Ra Medical, that you will be hearing about A LOT over the next year as they have developed breakthrough medical laser technology. She hit the ground running when her co-founder Dean Irwin developed a breakthrough laser technology to send dermatological diseases such as vitiligo and psoriasis into remission and is now in the middle of an FDA study for a cardiovascular laser to unclog arteries, which doctors have told me is a 'GAME CHANGER'. They had NO BUDGET in the beginning for a sales or marketing team, and so she shares some CREATIVE ways she was able to get attention and drive revenue for their dermatology business! They became profitable just a couple of years in and thanks to frugality as well in accepting hand-me-down furniture such as desks, lights, and more, they were able to reinvest all of that into R&D for their cardiovascular laser. During the show you’ll hear about how her background, including time at pharmaceutical company, Eli Lily, and marketing Cialis, the erectile dysfunction drug, and her marketing tactics she used to get consumers to buy into a brand they’d never heard of and didn’t want to admit they needed. She also offers some fantastic approaches to building relationships, getting attention for your brand, and creating the ultimate sales team on a limited or no budget.

Cathleen McCandless, is a nationally known and highly respected Feng Shui consultant, teacher and speaker with over twenty years experience. Known for her practical, common-sense style, warm personality, vast knowledge and expertise, Cathleen’s clientele includes Intel Corporation, Nike Corporation, Eli Lily, John Laing Homes, Alaska Airlines, Barratt Homes, D.R. Horton, Honeywell, Loews Luxury Hotels, and many others. She joins Life Mastery Radio with Todd Alan to discuss how to master one’s environment. Currently, her expertise is featured in a thirteen episode nation-wide television series called “Feng Shui Living”. Her book, Feng Shui That Makes Sense, can be purchased from her website: www.sandiegofengshui.com.